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Low birth weight, a form of fetal growth compromise, is a well-established risk 
factor for Attention-Deficit/Hyperactivity Disorder (AD/HD; Nigg, Nikolas, & Burt, 
2010); however, it is unclear how birth weight moderates genetic risk for AD/HD. From a 
Developmental Origins of Health and Disease (Gluckman & Hanson, 2004) framework, 
this study investigated if fetal growth compromise moderated relationships between SNPs 
within angiogenic, dopaminergic and neurotrophic genes and AD/HD symptom severity. 
A total of 398 youth from two multi-site, family-based studies of AD/HD were included 
in the current analysis. Results demonstrated that fetal growth compromise moderated 
associations between SNPs within angiogenic (HIF1A and NRP1) and a neurotrophic 
gene (NTRK3), but not dopamine genes, and AD/HD symptom severity. The gene x 
environment interactions remained significant after controlling for SNPs associated with 
birth weight and adjusting for multiple testing. Taken together, findings may suggest that 
prenatal ischemia/hypoxia is an environmental pathogen for AD/HD which confers 
vulnerability for the disorder through regulating the expression of angiogenic and 
neurotrophic genes. 
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CHAPTER I 
INTRODUCTION 
 
Most biological theories of attention-deficit/hyperactivity disorder (AD/HD; 
American Psychiatric Association [APA], 2000) identify dopaminergic dysfunction as the 
primary pathway to AD/HD (e.g., Levy, 1991).  These theories, which suggest that 
hypodopaminergic functioning in frontal and limbic neural systems underlie AD/HD 
symptomatology, have had some success in guiding AD/HD etiological research and the 
development of pharmacotherapies for the disorder (Swanson et al., 2007). Recent 
evidence from molecular genetic (Franke, Neale, & Faraone, 2009; Poelmans, Pauls, 
Buitelaar, & Franke, 2011) and environmental studies on AD/HD (see Banerjee, 
Middleton, & Faraone, 2007 for a review) implicate a broader range of 
neurodevelopmental processes in the etiology of the disorder.  These findings emphasize 
AD/HD’s vast etiological heterogeneity and highlight the limitations of the dopamine 
hypothesis in accounting for the numerous developmental pathways that result in the 
disorder.  
Two additional neurodevelopmental systems which may confer vulnerability for 
AD/HD include: 1) neurotrophic factors (Ribasés et al., 2008), which promote nerve 
survival, differentiation and growth; and 2) angiogenic factors (Jesmin et al., 2004; 
Weber, Lurschg, & Fahnenstich, 2005), which promote the formation of new blood 
vessels.  To date, there has been inconsistent evidence implicating neurotrophic factors in
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the etiology of AD/HD (Gizer, Ficks, & Waldman, 2009; Sanchez-Mora et al., 2009) and 
limited investigation of angiogenic factors.  One explanation for the inconsistency or lack 
of findings may be the failure to specify an environmental pathogen in vulnerability 
models for the disorder.  Given that both neurotrophic and angiogenic factors are 
regulated by environmental pathogens (Mill & Petronis, 2008; Schmidt-Kastner, van Os, 
Steinbusch, & Schmitz, 2006), the impact of neurotrophic and angiogenic factors on 
vulnerability for AD/HD may be dependent upon environmental risk. Therefore, the 
purpose of this project is to better understand the interaction of dopaminergic, 
neurotrophic and angiogenic factors with environmental conditions in conferring risk for 
AD/HD.  
 As background, it is first necessary to provide an overview of AD/HD, with an 
emphasis on the etiology of AD/HD. Next, research examining the genetic and 
environmental underpinnings of AD/HD will be reviewed. Then, the potential role of 
dopaminergic, neurotrophic and angiogenic factors in the etiology of AD/HD will be 
outlined. Finally, the research questions and hypotheses of this study are stated within a 
Developmental Origins of Health and Disease (DOHaD; Gluckman & Hanson, 2004) 
framework.   
AD/HD Overview 
There are five diagnostic criteria that need to be met to be diagnosed with one of 
the three AD/HD subtypes (Combined Type, Predominantly Inattentive Type, and 
Predominantly Hyperactive-Impulsive Type; APA, 2000). The five re-ordered DSM-IV 
criteria (Anastopoulos & Shelton, 2001) are: 1) clear evidence of clinically significant 
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impairment; 2) impairment in two or more settings related to AD/HD symptoms; 3) 
evidence for at least 6 out of 9 symptoms of inattention and/or hyperactivity-impulsivity, 
which have persisted for at least 6 months, and are developmentally deviant; 4) some 
symptoms causing impairment were present before 7 years of age; and 5) the symptoms 
cannot be better accounted for by another mental disorder.   
When all five diagnostic criteria are applied to representative community samples, 
the average prevalence rate of AD/HD in children and adolescents is between 5-5.5% 
(Polanczyk, De Lima, Horta, Biederman, & Rohde, 2007); however, rates vary by gender 
and age.  In terms of gender, DSM-IV (APA, 2000) reports that boys are 4 to 9 times as 
likely as girls to meet criteria for the disorder; however, these estimates are based largely 
on clinical samples.  Evidence from community samples (Polanczyk et al., 2007) 
suggests that boys are approximately 2.5 times as likely to meet criteria for the disorder. 
AD/HD rates tend to decrease with age (Polanczyk et al., 2007) and approximately 50-
80% of children diagnosed with AD/HD in childhood continue to display clinically 
significant symptom levels into adolescence (Barkley, Fischer, Edelbrock, & Smallish, 
1990). These symptoms also persist into adulthood, albeit at relatively lower rates 
(Mannuzza, Klein, Bessler, Malloy, & Hynes, 1997). The reduction in AD/HD 
prevalence over time may reflect neurodevelopmental normalization over time (Shaw et 
al., 2006) and/or developmentally inappropriate DSM-IV AD/HD diagnostic criteria for 
adolescents and adults (McGough & Barkley, 2004).   
Approximately 60% of individuals diagnosed with AD/HD meet diagnostic 
criteria for another psychological disorder (e.g., Pfiffner et al., 1999), including 
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oppositional defiant disorder, conduct disorder, learning disorders, anxiety disorders, 
depressive disorders, and tic disorders.  Furthermore, individuals with AD/HD are at 
heightened risk for delays in cognitive, language and motor development (Barkley, 
2006). Taken together, the variability in symptomatology, course, comorbid profiles and 
associated features within AD/HD demonstrates that AD/HD is marked by phenotypic 
heterogeneity.   
Given the magnitude of AD/HD related impairment and the major public-health 
cost of the disorder (Pelham, Foster, & Robb, 2007), there has been much interest in 
identifying the etiological underpinnings of AD/HD. Broadening the understanding of the 
etiology of AD/HD will help to reduce the public health impact of AD/HD both indirectly 
and directly by: 1) continuing to inform AD/HD taxonomy and classification; and 2) 
helping to identify malleable environmental pathogens and epigenetic mechanisms that 
can be targeted to reduce the prevalence of AD/HD. 
AD/HD Etiology 
 AD/HD is a multifactorial disorder arising from a variety of genetic, 
neurobiological and environmental factors (Nigg, 2006). Most putative etiological factors 
have been identified by comparing individuals with AD/HD and individuals without 
AD/HD. Thus, little is known about etiological variability within AD/HD or specific 
etiological pathways to AD/HD. 
Neurotransmission.  Most AD/HD etiological theories implicate dysfunctional 
neurotransmission as the main pathway to AD/HD.  For instance, the dopamine 
hypothesis of AD/HD (Levy, 1991; Swanson et al., 2007) indicates that 
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hypodopaminergic functioning in specific neural pathways is one major underpinning of 
AD/HD.  Although the dopaminergic system has been the most widely researched 
neurotransmitter system related to AD/HD, serotonergic, adrenergic, and cholinergic 
neurotransmitter systems have also been implicated (Biederman & Faraone, 2002; 
McClernon & Kollins, 2008; Pliszka, McCracken, & Maas, 1996).  The neurotransmitter 
hypotheses have helped to guide etiological research and treatment development for 
AD/HD; however, neurofunctional and neuroanatomical studies implicate a broader 
range of neurodevelopmental processes in the etiology of AD/HD.   
Neurofunctional deficits. In addition to abnormal neurotransmission, individuals 
with AD/HD demonstrate hypoactivation in particular neural regions during cognitive 
tasks.  This hypoactivation tends to occur in the prefrontal and limbic regions which are 
presumed to underlie AD/HD symptoms (Barkley, 1997; Durston, De Zeeuw, & Staal, 
2009). Though neurotransmitter deficits are the most widely cited contributor to the 
observed hypoactivation in these brain regions (e.g., Swanson et al., 2007), other factors 
may also be implicated. For instance, decreased cerebral blood flow to prefrontal and 
limbic regions may also underlie the neural hypoactivation (Gustafsson, Thernlund, 
Ryding, Rosen, & Cederblad, 2000; Kim, Lee, Shin, Cho, & Lee, 2002). Todd and 
Botteron (2001) have also proposed that deficient astrocyte glucose metabolism may be 
associated with prefrontal and limbic hypoactivation in AD/HD.  
Neuroanatomical structure.  Multiple neuroanatomical correlates of AD/HD 
have also been identified.  In general, individuals with AD/HD have reduced overall 
brain volumes, with an average reduction of approximately 5% (Castellanos et al., 2002). 
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In addition, multiple studies have identified the largest differences between individuals 
with AD/HD and controls in the prefrontal cortex, basal ganglia (e.g., caudate and 
putamen), corpus callosum and cerebellum (Valera, Faraone, Murray, & Seidman, 2007) 
- all of which are implicated in executive functioning processes which are impaired in 
many individuals with AD/HD (Barkley, 1997).  Furthermore, reduction in volume has 
been observed in both white and gray matter in the right (Filipek et al., 1997; Overmeyer 
et al., 2001) and left prefrontal cortices (Kates et al., 2002; Mostofsky, Cooper, Kates, 
Denckla, & Kaufmann, 2002).  These anatomical differences are apparent in childhood 
and are generally stable into adolescence, which suggests a non-progressive 
neurodevelopmental deficit (Castellanos et al., 2002).  However, Shaw et al. (2006) 
found that some individuals diagnosed with AD/HD who demonstrated increased cortical 
thickness over time also showed lagged reduction in AD/HD symptomatology, 
suggesting that some individuals with AD/HD have neurodevelopmental delays which 
normalize over time.  
Taken together, neurodevelopmental vulnerability for AD/HD is dimensional in 
nature and gives rise to a range of inattentive and hyperactive-impulsive symptoms 
(Shaw et al., 2011), which at their extreme meet the symptom criterion for the disorder. 
Neurodevelopmental risk for AD/HD consists of a myriad of neurotransmitter, 
neurofunctional, and neuroanatomical abnormalities which likely reflect both stable 
neurodevelopmental deficits (Castellanos et al., 2002) and neurodevelopmental delays 
(Shaw et al., 2006). Although the exact origins of neurodevelopmental risk for AD/HD 
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remain largely unknown, neurodevelopmental risk results from the interplay between 
genetic and environmental risk factors.   
Overview of AD/HD Genetic Studies 
Behavioral genetics.  Findings from family, adoption, and twin studies suggest 
that genetic factors play a substantial role in the etiology of AD/HD. For example, in an 
exanimation of parent-child concordance, offspring of adults diagnosed with AD/HD 
have approximately a 50% chance of also meeting diagnostic criteria for the disorder 
(Biederman, Faraone, Mick, & Spencer, 1995). To disentangle the relative influences of 
genetic and environmental effects on AD/HD, Faraone et al. (2005) analyzed 20 separate 
twin studies in which AD/HD was defined using parent report.  Results suggested that 
76% of AD/HD phenotypic heterogeneity in the population is accounted for by genetic 
factors.  Non-shared environmental factors (i.e., factors that make twins different from 
one another) accounted for roughly a quarter of the phenotypic heterogeneity in parent-
reported AD/HD, but shared environmental factors (i.e., factors that make twins more 
alike) did not account for unique variability in the AD/HD phenotype.  This suggests that 
although the genetic contribution to the etiology of AD/HD is paramount, environmental 
factors also play a substantial role.  These findings have important implications for 
research examining causal factors of AD/HD.   
Molecular genetics.  Given the size of the heritability estimate, many molecular 
genetic studies have attempted to identify specific genes that underlie the AD/HD’s 
genetic vulnerability.  Findings from candidate gene studies of AD/HD generally support 
the neurotransmitter hypotheses of AD/HD.  For example, genes associated with 
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dopaminergic functioning (DAT1, DRD4 and DRD5), serotonergic functioning (5HTT 
and HT1RB) and cholinergic functioning (CHRN14) were found to be associated with 
AD/HD. In addition, SNAP25, which is associated with axonal growth and synaptic 
plasticity, was also found to be associated with AD/HD (Gizer et al., 2009). Though such 
findings support etiological theories of AD/HD, the magnitude of association between 
candidate genes and AD/HD has been small and variable across studies.  For example, 
Gizer et al. (2009) recently conducted a meta-analysis of candidate gene studies of 
AD/HD whichshowed that 11 genetic variants (some within the same gene) had a small 
to modest association with AD/HD (Odds Ratios ranged from 1.12-1.33).  
 In response to the inconsistent association between candidate genes and AD/HD, 
exploratory Genome-Wide Association Studies (GWAS) have attempted to uncover new 
AD/HD risk genes and replicate those found in previous candidate gene studies.  
Unfortunately, AD/HD genome-wide association studies have found few regions of 
overlap between studies (Lasky-Su et al., 2008a; Lasky-Su et al., 2008b; Lesch et al., 
2008; Neale et al., 2008a) and little support for classic AD/HD candidate genes (Franke 
et al., 2009).  Instead, evidence across AD/HD genome-wide association studies  
implicate  genes associated with more basic cellular processes including cell-cell 
communication, cell division, cell adhesion, neuronal migration, and neural plasticity in 
the etiology of AD/HD (Franke et al., 2009; Poelmans et al., 2011); however,  AD/HD 
genome-wide association studies have yet to detect genes at the level of genome-wide 
significance.   
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 Together, candidate-gene and genome-wide association studies suggest that both 
neurotransmission and more basic cellular processes (e.g., plasticity) influence 
vulnerability for AD/HD.  Although a handful of candidate genes are associated with 
AD/HD, the molecular genetic contribution to AD/HD’s heritability estimate is still 
largely unknown.   Multiple sources are likely to underlie AD/HD’s “hidden heritability” 
including rare genetic variants (e.g., Copy Number Variants) that have a large effect in 
individuals but are uncommon in the population (McCarthy & Hirschhorn, 2008), gene-
gene interactions (Derks et al., 2008), gene-environment correlation and gene x 
environment interactions (GxE; Rutter, Moffitt, & Caspi, 2006).  For example, molecular 
genetic studies that fail to incorporate environmental measures may fail to uncover 
AD/HD vulnerability genes that are dependent on exposure to an environmental 
pathogen. Although genetic factors have the largest impact on the etiology of AD/HD, 
behavioral genetic studies indicate that non-shared environmental factors also play a 
substantial role in the etiology of the disorder.  To better elucidate pathways to AD/HD, 
etiological models of the disorder need to specify both genetic and environmental factors. 
 Environmental Factors Associated with AD/HD 
Many environmental risk factors have been associated with AD/HD.  Although 
typically referred to as “environmental” risk factors in the psychological literature, many 
of these risk factors have substantial heritability estimates (e.g., Kendler & Baker, 2007). 
Thus, observed associations between environmental risk factors and AD/HD may not be 
entirely “environmental” in nature.  Furthermore, environmental risk factors tend to 
congregate together (e.g., Knopik et al., 2006); therefore, before determining if a causal 
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relationship between an environmental factor and AD/HD exists, one must rule-out the 
role of confounding genetic and environmental factors. 
The most extensively studied environmental factors associated with AD/HD are 
relatively uncommon and are believed to confer risk for AD/HD early in life.  
Specifically, exposure to prenatal teratogens has been a major focus of study, with 
prenatal exposure to smoking and alcohol garnering the most attention.  Findings 
generally suggest that prenatal exposure to smoking and alcohol is associated with 
increased risk for AD/HD (Linnet et al., 2003), though the magnitude of association is 
small.  In addition, the route to AD/HD risk from these and other prenatal teratogens is 
still largely unknown.  Exposure to prenatal smoking may covary with genetic risk for 
AD/HD as parents with AD/HD may be at increased risk to smoke and consume alcohol 
during pregnancy (Burke, Loeber, & Lahey, 2001).  However, after parental AD/HD is 
statistically controlled for, prenatal exposure to nicotine is still associated with AD/HD 
(Milberger, Biederman, Faraone, Chen, & Jones, 1996; Milberger, Biederman, Faraone, 
& Jones, 1998).  In addition to early exposure to teratogens, prenatal hypoxia has been 
associated with increased risk for AD/HD (Ben Amor et al., 2005; Pineda et al., 2007).  
Exposure to other toxicants (lead, mercury and manganese) and post-natal environmental 
factors such as environmental deprivation and trauma have been examined to a lesser 
degree (Banerjee et al., 2007). Interestingly, many of these prenatal environmental factors 
restrict nutrient availability in utero and are associated with fetal growth compromise 
(Kramer, 1987). Although many prenatal environmental risk factors increase risk for 
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AD/HD, it remains relatively unclear how environmental factors confer risk for AD/HD 
and how genes may moderate environmental risk.  
GxE in AD/HD 
Investigating the interplay between genes and environment on AD/HD will build 
on research examining their independent effects and may: 1) account for AD/HD’s 
hidden heritability estimate (Nigg, 2006), 2) explain variability AD/HD outcomes in 
individuals exposed to environmental risk factors; and 3) further the search of causal 
pathways to AD/HD.  GxE studies in AD/HD (Nigg et al., 2010) have investigated the 
interaction of classic AD/HD candidate genes with a wide variety of putative 
environmental risk factors including prenatal smoking exposure (Altink et al., 2008; 
Becker, El-Faddagh, Schmidt, Esser, & Laucht, 2008; Kahn, Khoury, Nichols, & 
Lanphear, 2003; Neuman et al., 2007; Todd & Neuman, 2007), prenatal alcohol exposure 
(Brookes et al., 2008), season of birth (Brookes et al., 2008; Seeger, Schloss, Schmidt, 
Rüter-Jungfleisch, & Henn, 2004), exposure to psychosocial adversity (Laucht et al., 
2007; Retz et al., 2008; Sonuga-Barke et al., 2008; Sonuga-Barke et al., 2009; Waldman, 
2007) and birth weight (Langley et al., 2008).  Although GxE studies have helped to 
broaden our understanding of the etiology of AD/HD, inconsistent findings and lack of 
methodological rigor have limited implications from this body of research (Ficks & 
Waldman, 2009; Nigg et al., 2010).   
Indirect and retrospective measurement of the environmental exposure is one 
example of lack of methodological rigor in AD/HD GxE studies. For instance, many GxE 
studies examining prenatal exposure cigarette and alcohol use rely on a mother’s report 
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of her cigarette or alcohol use during pregnancy (Altink et al., 2008; Brookes et al., 
2006b; Langley, Holmans, Van Den Bree, & Thapar, 2007; Neuman et al., 2007; Todd & 
Neuman, 2007), both of which have been shown to have limited reliability(Derauf, Katz, 
& Easa, 2003).  In addition, the precision of AD/HD phenotype measurement is highly 
variable and many studies conduct group based analyses using arbitrary criteria to define 
AD/HD and non-AD/HD groups. For example, Laucht et al. (2007) dichotomized their 
community sample into two groups (one with zero AD/HD symptoms and the other with 
at least one AD/HD symptom). Such an approach does not match the dimensional nature 
of AD/HD (Levy, Hay, McStephen, Wood, & Waldman, 1997; Shaw et al., 2011). It is 
also unclear how reliable such classifications are over time. The loss of reliability in the 
measure of the environmental factor or outcome may produce false negatives, especially 
when the studies are underpowered (Moffitt, Caspi, & Rutter, 2006).  
Moreover, GxE studies fail to account for the significant heritability components 
of  environmental risk factors (Kendler & Baker, 2007). This suggests that findings of the 
association between the environmental risk factor and AD/HD may be confounded by a 
shared genetic liability.  Finally, studies often do not provide an explanation of the 
biological mechanism of action. For example, most AD/HD GxE studies examine 
interactions between dopamine genes and environmental pathogens; however, little to no 
rationale is provided for why an environmental pathogen would moderate the effect of a 
dopaminergic genotype on vulnerability for AD/HD. To improve upon previous studies, 
it is essential for future studies to provide a framework for how genetic and 
environmental factors coalesce to influence vulnerability for AD/HD.  
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Developmental Origins of Health and Disease  
The Developmental Origins of Health and Disease hypothesis (DOHaD; 
Gluckman & Hanson, 2004) provides a framework to conceptualize how genetic and 
early environmental factors interact to confer vulnerability for AD/HD.  Briefly, DOHaD 
purports that adverse influences, during critical periods of development, lead to fetal 
growth compromise.  In addition to restricting nutrient and oxygen supply in utero, such 
influences may also lead the organism to make structural and functional adaptations to 
adverse environmental influences. To the extent that there is a mismatch between the 
prenatal and postnatal environments, the organism, which has adapted to increase 
probability of survival during prenatal development, may be ill-equipped to function 
adaptively in the future.  This mismatch confers vulnerability for later disease as the 
organism is functioning in an environment for which it did not prepare. In addition to 
predicted adaptive responses, a restricted nutrient supply in utero may also constrain, 
delay, or disrupt developmental plasticity or developmental processes.  
In the case of AD/HD, neurodevelopmental delays or neurodevelopmental 
disruptions may result from a limited supply of nutrients and oxygen in utero. Within 
individuals exposed to a restricted nutrient supply, and who subsequently have restricted 
fetal growth, vulnerability for AD/HD may then be moderated by the individual’s 
genotype, maternal genotype, epigenetic changes, and the postnatal environment (see 
Figure 1). Such a conceptual model has yet to be tested. Prior to pursuing this line of 
research, it is first necessary to clarify the relationship between fetal growth compromise 
and AD/HD.   
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Fetal Growth Compromise in GxE studies of AD/HD 
Moffitt et al. (2006) suggest that an environmental risk factor should be 
considered for use in a GxE study if: 1) individuals demonstrate a variable response after 
being exposed to the factor; 2) the environmental risk factor has a plausible effect on 
pathophysiology of the disorder; and 3) if there is evidence that the environmental risk 
factor is pathogenic in nature.  These criteria help to ensure that the environmental risk 
factor is causal and that genetic factors are able to moderate the relationship between the 
environmental risk factor and outcome of interest. For the purpose of this study, the 
environmental factor under consideration is a restricted nutrient supply in utero; however, 
in human studies, this factor is rarely measured directly.  Instead, nutrient supply in utero 
is often measured indirectly through fetal growth compromise (Maulik, 2006).  
Therefore, the following discussion will focus on the relationship between fetal growth 
compromise, as an indicator for restricted nutrient supply in utero, and AD/HD.  
Variability in AD/HD outcome in fetal growth compromise.  Across 22 
prospective case-control studies examining the association between birth weight and 
AD/HD, individuals who were Low Birth Weight (LBW), Small for Gestational Age 
(SGA) or Intrauterine Growth Restricted were at two times greater risk of developing 
AD/HD compared to control groups with average fetal growth (Smith, Unpublished 
Manuscript).  The magnitude of association between individuals who experienced 
restricted fetal growth and AD/HD is greater than that of any common candidate genes 
(Gizer et al., 2009). In addition, AD/HD risk increased as more comprehensive AD/HD 
assessments were employed (Botting, Powls, Cooke, & Marlow, 1997; Breslau et al., 
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1996; Indredavik et al., 2004), suggesting that error in AD/HD assessment reduces the 
observed association between fetal growth compromise and AD/HD.  Similar findings 
were also reported in retrospective AD/HD case-control studies (e.g., Mick, Biederman, 
Prince, Fischer, & Faraone, 2002).  Finally, evidence from population cohort (Boulet, 
Schieve, & Boyle, 2009) and twin-studies  (van Os et al., 2001) suggest that as fetal 
growth decreases, risk for AD/HD and externalizing behavior problems increases, 
respectively.  Together, these three lines of evidence suggest that: 1) individuals who 
experienced fetal growth compromise are at increased risk for AD/HD; and 2) there is 
variability in AD/HD outcomes in those exposed to fetal growth compromise, regardless 
of the severity of fetal growth compromise (Hack et al., 2009). Therefore, the variability 
in AD/HD outcomes among those exposed to fetal growth compromise may be related to 
individual genetic factors. 
Fetal growth compromise on pathophysiology of AD/HD.  There is much 
evidence to suggest that the relationship between fetal growth compromise and AD/HD 
holds true even after numerous covariates are taken into account.  For example, the 
relationship between birth weight and AD/HD cannot be accounted for by child factors 
such as sex, season of birth or duration of breast feeding (Elgen, Sommerfelt, & 
Markestad, 2003; Horwood, Mogridge, & Darlow, 1998) or by parental factors such as 
marital status, age, maternal education, paternal education, maternal stress, parental 
psychopathology, substance abuse, maternal smoking, or parental nurturance (Breslau et 
al., 1996; Elgen et al., 2003; Horwood et al., 1998; Indredavik et al., 2004; Linnet et al., 
2006; Zubrick et al., 2000).   
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Furthermore, there are plausible biological processes that may link fetal growth 
compromise with AD/HD. For example, the second and third trimesters are critical 
periods in brain development, most notably for neurogenesis, neural migration, dendrite 
formation and synapse formation (Rodier, 2004).  Therefore, prenatal insults during this 
period of development have the potential of restricting fetal growth and have lasting 
effects on neurodevelopment.  For instance, growth restricted infants had reductions in 
overall white and gray matter compared to normally grown infants (Brown et al., 2009; 
Larroque et al., 2003; Tolsa et al., 2004). Such reductions relate to poorer performance on 
early measures of attention, more negative neurodevelopmental outcomes (Peterson et al., 
2003; Tolsa et al., 2004) and are consistent with findings in AD/HD samples (Filipek et 
al., 1997; Kates et al., 2002; Mostofsky et al., 2002; Overmeyer et al., 2001).  In addition 
to between group findings, neuroanatomical abnormalities predict increased risk for 
AD/HD within a fetal growth restricted cohort (Whitaker et al., 1997); however, it 
remains largely unclear why some individuals who experience fetal growth compromise 
develop AD/HD while others do not.  Together, these findings suggest that youth who 
have experienced fetal growth compromise tend to display neurodevelopmental 
abnormalities which are functionally related to AD/HD symptomatology and consistent 
with findings in AD/HD samples.  
Fetal growth compromise as a marker for an environmental pathogen.  
Evidence suggests that exposure to environmental factors that contribute to fetal growth 
compromise cause neurodevelopmental deficits consistent with AD/HD.  For example, in 
multiple studies of monozygotic AD/HD discordant twins, the AD/HD affected co-twins 
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tended to have lower birth weights compared to the unaffected co-twins (Lehn et al., 
2007; Sharp et al., 2003).  In addition, MRI studies of discordant monozygotic AD/HD 
twins found that the AD/HD twin had a smaller caudate volume (Castellanos et al., 2003) 
and reductions of gray and white matter in the dorsolateral prefrontal cortex and corpus 
callosum (van 't Ent et al., 2007).  Although genetic effects cannot be ruled out in the 
general population, findings from monozygotic discordant twin studies suggest that 
environmental or non-genetic factors contribute to differences in neurodevelopmental 
deficits and AD/HD symptomatology. 
Furthermore, both prospective and retrospective case-control studies demonstrate 
that the relationship between birth weight and AD/HD cannot be accounted for by 
parental AD/HD or parental psychopathology (e.g., Indredavik et al., 2004; Mick et al., 
2002).   Population twin studies (van Os et al., 2001; Wichers et al., 2002) also report that 
a shared genetic variable cannot account for the relationship between birth weight and 
child behavior problems. Therefore, although genetic effects cannot be entirely ruled out, 
fetal growth compromise represents a constellation of prenatal environmental risk factors 
(i.e., non-genetic) which compromise fetal growth and are pathogenic in nature.  
Optimizing measurement of fetal growth compromise. Moffitt et al. (2006) 
also emphasize the importance of accurately and reliably measuring the putative 
environmental risk factor in GxE research.  Many different measures of fetal growth and 
fetal growth compromise are made both prenatally and at birth.  Although LBW 
(weighing less than 2500 grams at birth) has been the most widely studied fetal growth 
phenotype in the AD/HD literature, LBW lacks specificity and may identify individuals 
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who are either constitutionally small or premature, but normally grown. Therefore, 
measures of asymmetric growth restriction, such as ponderal index which measures 
weight relative to length, or measures of fetal growth for gestational age, may be more 
appropriate in identifying individuals at risk for AD/HD, as they are less likely to be 
influenced by factors that do not limit fetal growth (Maulik, 2006).  
Measures of asymmetric growth compromise offer a good option for indirectly 
measuring a restricted nutrient supply in utero (Gluckman & Hanson, 2004; Maulik, 
2006); however, measures of birth length are not always recorded in population birth 
registries or birth records. In the absence of measures of birth length, measures of fetal 
growth for gestational age (e.g., small for gestational age) are a reasonable alternative.  
Given that appropriately grown individuals that are born premature are not at increased 
risk for AD/HD (Heinonen et al., 2010), SGA is considered a better indicator of risk for 
AD/HD due to a restricted nutrient supply in utero. 
For clinical purposes SGA is typically dichotomized (i.e., <10
th
 percentile = SGA; 
≥ 10
th
 centile = appropriate for gestational age). A dichotomous measure of SGA, 
however, is not consistent with the continuous nature of association between fetal growth 
compromise and AD/HD (Boulet et al., 2009; van Os et al., 2001) and would reduce 
statistical power in a GxE model. Therefore, in models of AD/HD risk, it is most 
appropriate to measure SGA continuously, through customized birth weight centiles. 
Given that birth weight varies by sex, ancestry, and parity, SGA calculations are often 
customized to account for such differences through the use of appropriate reference 
groups (e.g., Visser, Eilers, Elferink-Stinkens, Merkus, & Wit, 2009).   
 
19 
 
 One limitation of many current GxE studies is the use of retrospective 
measurements of the environmental pathogen and the resulting loss in reliability (Moffitt 
et al., 2006). Although measurement at birth is considered the most reliable time of 
assessment, birth record review has been shown to be a reliable approach to measuring 
birth phenotype (Northam & Knapp, 2006).   In the absence of medical or birth records, 
maternal recall of birth weight and gestational age has also been used in epidemiological 
and clinical research.  The reliability of maternal recall of birth weight and gestational 
age is high, with around 75% of mothers recalling birth weight within 100g of the 
recorded birth weight and within one week of the recorded gestational age (Seidman, 
Slater, Ever‐Hadani, & Gale, 1987).  
Selection of candidate systems to moderate the association between fetal 
growth compromise and AD/HD.  In a DOHaD framework, the association between 
fetal growth compromise and AD/HD is likely moderated by genotype.  There are many 
different approaches to choosing genes to interact with fetal growth compromise. Most 
previous GxE studies in AD/HD have chosen candidate genes that have a direct 
association with the disorder. This approach has a limited conceptual basis and may be 
related to the inconsistent findings in the AD/HD GxE literature (Ficks & Waldman, 
2009).  In contrast, Moffitt et al. (2006) suggest choosing candidate polymorphisms 
based on their functional significance in relation to the environmental risk factor.  
Consistent with this approach, systems that influence vulnerability for AD/HD and whose 
expression is regulated by restricted nutrient and oxygen supply include the 
dopaminergic, neurotrophic and angiogenic pathways. 
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Dopaminergic system. Hypodopaminergic functioning is a central component to 
most AD/HD etiological theories (Barkley, 1997; Levy, 1991; Nigg & Casey, 2005; 
Sagvolden, Johansen, Aase, & Russell, 2005; Sonuga-Barke, 2002). Dopaminergic 
functioning is highly complex (see Missale, Nash, Robinson, Jaber, & Caron, 1998 for a 
review) and is influenced by a multitude of factors including dopamine synthesis and 
delivery, dopamine receptors and dopamine termination. The dopaminergic system is 
embedded in the larger catecholamine pathway and is involved in, among other things, 
cognitive, behavioral, and emotional functioning (Missale et al., 1998). Dopamine plays a 
central role in the regulation of prefrontal cortical neural activity which project to the 
nucleus accumbens and ventral tegmental area (Sagvolden et al., 2005). The 
mesocortical, mesolimbic, and nigrostraital neural loops are largely regulated by 
dopamine and are believed to impact hyperactivity-impulsivity, inattention and motor 
inhibition, respectively (Sagvolden et al., 2005).  
Evidence implicating dopamine in the etiology of AD/HD comes from animal 
research and human genetic research. For example, common AD/HD animal models 
(e.g., the Spontaneously Hypertensive Rat, DAT knockout mouse and the SNAP-25 
deficient mutant coloboma mouse) have genetic abnormalities which lead to 
hypodopaminergic functioning and AD/HD like behaviors (Russell, 2011).  Such findings 
are also consistent with results in human genetics studies. For example, polymorphisms 
within dopamine receptors (DRD4 and DRD5), the dopamine transporter (DAT1) and a 
factor involved with dopamine delivery (SNAP-25) are all associated with AD/HD (Gizer 
et al., 2009).    
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There is substantial support linking hypodopaminergic functioning with AD/HD; 
however, far less is known about how environmental factors influence dopaminergic 
functioning.  Initial research has shown that intermittent hypoxia or malnutrition has led 
to reduced extracellular dopamine in the prefrontal cortex in rats (Decker, Jones, 
Solomon, Keating, & Rye, 2005; Mokler, Torres, Galler, & Morgane, 2007), which may 
be mediated by hypoxia-inducible factor (HIF) which promotes cell survival in hypoxic 
conditions (Johansen et al., 2010). In addition, many GxE studies have examined if 
prenatal environmental risk moderates the association between dopamine genes and 
AD/HD, but findings have been mixed (Nigg et al., 2010). 
Neurotrophic system. The neurotrophin family promotes numerous 
neuroadaptive functions including neuron survival, neural differentiation, neural 
plasticity as well as synaptic efficiency in both the central nervous system and the 
peripheral nervous system.  This family consists of four closely related proteins including 
nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 
(NT-3) and neurotrophin-4 (NT-4) that are derived from their relative proneurotrophins.  
These factors bind to and activate one or more of the tyrosine kinase neurotrophin 
receptors (TrkA, TrkB, and TrkC).  In addition, all the mature neurotrophins and the 
proneurotrophins bind to and activate the low affinity p75 receptor (Reichardt, 2006; see 
Figure 3).  Although other factors (e.g., ciliary neurotrophic factor; glial derived 
neurotrophic factor) promote neural growth and differentiation, to date, the majority of 
research has focused on the neurotrophin family. In addition to being expressed in nerve 
cells, the neurotrophin family is also expressed in endothelial cells in the vasculature.  
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Lines of evidence from animal and human studies, including genetic and neuroimaging 
studies, suggest that neurotrophic factors may play a role in the etiology of AD/HD (see 
Ribasés et al., 2008).   
Mouse models suggest that neurotrophic factors play a critical role in survival, 
neural growth and behavior.  For example, homozygous BDNF knockout mice fail to 
survive past the second postnatal week (Ernfors, Lee, & Jaenisch, 1994) and 
heterozygous BDNF knockout mice display increased hyperactivity, aggression, 
decreased learning ability and dysregulated eating behavior (Kernie, Liebl, & Parada, 
2000; Linnarsson, Björklund, & Ernfors, 2006; Lyons et al., 1999). In addition, 
neurotrophic factors are also influenced by exposure to putative environmental 
pathogens. For example, BDNF expression is upregulated in the hippocampus during 
conditions of restricted nutrient supply (Schmidt-Kastner et al., 2001). Furthermore, 
decreases in BDNF expression lead to both hyperactivity and severe learning deficiencies 
in early but not later life (Monteggia et al., 2004). This suggests that the behavioral 
sequelae related to BDNF expression resemble AD/HD symptomatology and are 
temporally dependent.  
 To date, multiple human studies have investigated the role of genes encoding for 
neurotrophic factors in the etiology of AD/HD.  For example, three recent meta-analyses 
in both child and adult samples (Forero, Arboleda, Vasquez, & Arboleda, 2009; Gizer et 
al., 2009; Sanchez-Mora et al., 2009) have investigated the association between the 
BDNF gene and AD/HD.  Although individual studies have found a significant 
association between the BDNF Val66Met and AD/HD (Kent et al., 2005), NTF and 
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AD/HD (Syed, Dudbridge, & Kent, 2007), and NTF3, NTRK2 (the BDNF receptor) and 
AD/HD (Ribasés et al., 2008), meta-analyses found no association between SNPs within 
BDNF and AD/HD.  Such inconsistent results are common in psychiatric genetics.  One 
explanation for such inconsistency is that genetic variation in neurotrophic factors 
confers risk for AD/HD only under particular adverse environmental exposures.  To 
address this limitation, Lasky-Su and colleagues (2007) found that SNPs in the BDNF 
gene, including the Val66Met SNP, moderated the association between socio-economic 
status and AD/HD.  Similar to results in animal studies (Schmidt-Kastner et al., 2001), 
this finding suggests that the role of the neurotrophic family in the etiology of AD/HD 
may depend on environmental risk. 
Neuroimaging studies also provide groundwork to link neurotrophic factors and 
AD/HD. For example, consistent with findings in AD/HD (Valera et al., 2007), 
neuroimaging genetic studies suggest that compared to BDNF Val/Val homozygotes, 
BDNF Val/met heterozygotes had reduced anterior cingulated cortex, dorsolateral 
prefrontal cortex, hippocampus, and amygdala volumes (Nemoto et al., 2006; Sublette et 
al., 2008). In addition, the combination of early life stress and the BDNF met allele 
resulted in greater neuroanatomical deficits (Gatt et al., 2009).  
Taken together, findings suggest that to elucidate the role of neurotrophic factors 
in the development of AD/HD, it may be important to consider the environmental 
context. Given the high rate of neurodevelopment in the prenatal period, a limited 
nutrient supply in utero may moderate the expression of neurotrophic genes which would 
alter neurodevelopmental risk for AD/HD.    
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Angiogenic system. Angiogenesis, or the creation of blood vessels, is necessary 
for neural development, neural maintenance and neural function (Shibuya, 2008). In 
humans, the Vascular Endothelial Growth Factor (VEGF) family is the main regulator of 
angiogenesis (Shibuya & Claesson-Welsh, 2006).  The VEGF family consists of VEGF-
A, VEGF-B, VEGF-C, VEGF-D, and platelet-derived growth factor (PIGF), and their 
receptors VEGFR-1, VEGFR-2, and VEGFR-3.  VEGF-A has been the most extensively 
studied factor and VEGF-A promotes angiogenesis by binding to VEGFR-1 and VEGFR-
2. VEGF-B and PIGF bind to VEGFR-1 and also influences angiogenesis, albeit to a 
lesser extent (Shibuya, 2008). VEGF-C and VEGF-D bind to VEGFR-3 and play a 
central role in the formation of lymphatic vessels, and therefore will not be further 
discussed.   
VEGF-A homozygote and heterozygote knockout mice fail to survive past the 
embryonic stage due to maladaptive angiogenesis which suggests that VEGF-A protein 
provided by both VEGF-A alleles is necessary for survival (Ferrara et al., 1996).  In 
addition, decreases in the VEGF-A protein lead to tissue hypoxia and neural degeneration 
(Haigh et al., 2003). In terms of gene expression, environmental factors have also been 
shown to regulate the expression of VEGF and their receptors. For example, hypoxia 
produces an upregulation of the VEGF-A (Jaakkola et al., 2001). The upregulation of 
VEGF expression, as well as other genes that promote adaptation in the face of hypoxia, 
is mediated by the transcription factors of hypoxia inducible factors (HIF-1;  Mac 
Gabhann & Popel, 2008). Considering that hypoxia is a risk factor for 
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neurodevelopmental disorders, including AD/HD, the route to risk from angiogenic 
factors to AD/HD may depend on restricted nutrient and oxygen supply in utero.  
Animal models also suggest that reduced levels of angiogenic factors may play a 
role in the pathophysiology of AD/HD.  For example, a substrain of the spontaneously 
hypertensive rat (SHR; Okamoto & Aoki, 1963), which demonstrates vulnerability to 
stroke (Jesmin et al., 2004), exhibits behaviors consistent with AD/HD. Interestingly, the 
stroke-prone SHR has reduced VEGF serum levels compared to the SHR and Wistar-
Kyoto rat strains, suggesting the VEGF expression may be involved in the 
pathophysiology of AD/HD (Jesmin et al., 2004). In addition, the stroke-prone SHR also 
demonstrates abnormal regional cerebral blood flow (rCBF; Jesmin et al., 2004). 
Together, animal research suggests that the VEGF family is necessary for survival, 
interacts with the environment to influence VEGF expression, and VEGF may be 
associated with vulnerability for AD/HD via abnormal rCBF. 
To date, the role of the VEGF family in contributing to the pathophysiology of 
AD/HD in humans has not been examined; however, multiple studies have examined the 
role of rCBF in individuals diagnosed with AD/HD.  For example, findings have 
suggested that youth with AD/HD have decreased rCBF in prefrontal, limbic and 
cerebellar regions during resting state compared to controls (Kim et al., 2002).  In 
addition to functional changes in neuroanatomical substrates associated with AD/HD, 
genetic neuroimaging studies suggest that SNPs within the VEGF-A gene are associated 
with hippocampal volume (Blumberg et al., 2008).   
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Additional studies have examined the role of rCBF in mediating the therapeutic 
effects of methylphenidate. In general, studies suggest that responders to methylphenidate 
have increases in rCBF in the prefrontal cortex and caudate nucleus (Kim et al., 2002).  
Together, such findings have led Jesmin et al. (2004) to suggest that individual 
variability in VEGF concentration or angiogenic response to prenatal insults, like a 
reduced nutrient supply in utero, may compromise regional Cerebral Blood Flow (rCBF) 
in prefrontal and limbic systems which, in turn, increases vulnerability for AD/HD.   
Summary and Purpose 
Although AD/HD behavioral genetic studies have consistently demonstrated that 
genetic effects are paramount, non-shared environmental factors play a substantial role in 
the etiology of AD/HD. To date, molecular genetic studies have produced mostly 
inconsistent results (e.g., Franke et al., 2009; Gizer et al., 2009) and accounted for only a 
small proportion of the AD/HD heritability estimate (Nigg, 2006). Failure to include 
environmental factors within genetic studies of AD/HD may account, in part, for the 
inconsistent findings and help to explain AD/HD’s large heritability estimate. In addition, 
GxE studies have the potential to broaden our understanding of the etiology of AD/HD 
and help to uncover causal mechanisms which contribute to the development of AD/HD. 
Fetal growth compromise is a promising environmental risk factor for use in 
AD/HD GxE studies for the following reasons: 1) it is associated with increased risk for 
AD/HD; 2) it is associated with increased neurodevelopmental vulnerability for AD/HD; 
and 3) prenatal environmental factors underlie the relationship between fetal growth 
compromise and AD/HD. Together, this suggests that fetal growth compromise is an 
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indicator for prenatal environmental risk factors which restrict nutrient supply in utero, 
compromise fetal growth and are pathogenic in nature.   
Two previous studies have investigated fetal growth compromise in the context of 
an AD/HD GxE study (Langley et al., 2007; Langley et al., 2008). These studies did not 
provide a rationale for examining interactions between birth weight and dopamine and 
serotonin genes in predicting AD/HD and did not report any significant findings. This 
approach is consistent with the majority of AD/HD GxE studies which examine 
interactions between a variety of environmental risk factors and classic AD/HD candidate 
genes, but do not provide a rationale for predicting the presence of GxE.   
Therefore, to address this limitation, the current study was conceptually driven by 
the DOHaD hypothesis (Gluckman & Hanson, 2004). Given that ischemia/hypoxia is 
believed to underlie fetal growth compromise and is associated with the upregulation of 
dopaminergic, neurotrophic and angiogenic genes, there is reason to believe that fetal 
growth compromise may moderate the relationships between angiogenic, dopaminergic 
and neurotrophic genotypes and AD/HD. From a DOHaD perspective, in response to a 
restricted nutrient supply in utero, individual variability in dopaminergic, neurotrophic 
and angiogenic factors (Cannon, Yolken, Buka, & Torrey, 2008; Fu & Olofsson, 2006) 
may be associated with neurodevelopmental characteristics associated with AD/HD 
(Rapoport & Gogtay, 2007; Shaw et al., 2006; Toft, 1999) and give way to the AD/HD 
behavioral phenotype.  
To address this possibility, the purpose of this research project was to examine the 
interaction of polymorphisms in the dopaminergic, neurotrophic and angiogenic systems 
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with fetal growth compromise to predict AD/HD symptom severity.  Consistent with the 
DOHaD perspective (Gluckman & Hanson, 2004) the following hypotheses were made:  
1. Consistent with pervious findings, lower customized birth weight centiles 
were expected to be associated with increased AD/HD symptomatology. 
2. In an extension of previous research, it was predicted that after controlling 
for main effects, fetal growth compromise would moderate the 
relationship between SNPs within dopaminergic, neurotrophic and 
angiogenic genes and AD/HD symptom severity.   
The results of this research project will inform our conceptualization of the 
etiology of AD/HD by potentially helping to: 1) further our understanding of the role of 
dopaminergic, neurotrophic and angiogenic genes and vulnerability for AD/HD; 2) 
explain the variability in AD/HD outcome in individuals who experienced fetal growth 
compromise (e.g., Mick et al., 2002); and 3) shed light on causal mechanisms underlying 
the etiology of AD/HD.
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CHAPTER II 
METHOD 
 
Participants 
A total of 398 youth participated in the current study. Participants were drawn 
from multiple sites within the United States and Europe (see Table 1). Of the 398 total 
participants, 107 youth were from the North Carolina Genetics of AD/HD Project 
(NCGAP; PI – Allison Ashley-Koch, 1R01NS049067) with recruitment sites at Duke 
University and the University of North Carolina at Greensboro (UNCG). The remaining 
291 youth were drawn from the International Multisite AD/HD Genetics Project 
(IMAGE; PI-Stephen Faraone, R01MH081803, R01MH62873) with recruitment sites in 
Ireland, the Netherlands, and the United Kingdom.  
NCGAP is a longitudinal, family-based genetic study of AD/HD and its comorbid 
features.  AD/HD probands, AD/HD affected siblings, and unaffected siblings from 
NCGAP were included in the current study.   NCGAP probands: 1) were between the 
ages of 5-12 years; 2) met DSM-IV criteria for AD/HD; 3) had a full-scale IQ estimate of 
> 70 as measured by Block Design and Vocabulary subtests of the Wechsler Intelligence 
Scale for Children, Fourth Edition (WISC-IV; Wechsler et al., 2004)
1
; 4) had a Clinical 
Global Impression Scale (CGI; Guy, 1976) of ≥ 3; and 5) had a biological parent was 
                                                 
1
 If participant had an IQ estimate between 70 and 80, then a score > 70 was required on 
the Vineland Adaptive Behavior Rating Scale, Second Edition (Vineland-II; Sparrow, 
Cicchetti, & Balla, 2005) composite score.  
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available to participate. Families were excluded from participating in NCGAP if the 
identified proband: 1) met diagnostic criteria for a pervasive developmental disorder; 2) 
displayed significant developmental delays; or 3) had a medical, neurological or genetic 
disorder that could have accounted for the AD/HD symptomatology. 
In NCGAP, parent responses to a diagnostic structured interview and parent and 
teacher rating scale responses were used to establish Diagnostic and Statistical Manual of 
Mental Disorders – 4
th
 Edition (DSM-IV) AD/HD diagnostic status.  Youth met research 
criteria for AD/HD if they, when off medication: 1) had a positive diagnosis on the 
AD/HD module of the Computerized Diagnostic Interview Schedule for Children –IV 
(C-DISC-IV; National Institute of Mental Health [NIMH], 1997); 2) had T-scores ≥ 65 
and 60 on the parent and teacher forms of the Conners’ Rating Scale-Revised Long Form 
(CRS R:L; Conners, 1997) DSM-IV inattention and/or hyperactivity-impulsivity 
dimensions, respectively
2
; and 3) were determined to meet DSM-IV criteria for AD/HD, 
any subtype, by a panel of three senior investigators and licensed psychologists with 
expertise in AD/HD. The same criteria and panel review process were used for 
determining AD/HD status of all siblings participating in the study; however, siblings 
were not required to meet DSM-IV criteria for AD/HD and could range in age from 5 to 
17 years.  
The IMAGE study (Brookes et al., 2006a; Kuntsi, Neale, Chen, Faraone, & 
Asherson, 2006; Neale et al., 2008b) is a family-based AD/HD genetics project with 12 
participating sites in Belgium, Germany, Ireland, Israel, Spain, Switzerland and the 
                                                 
2
 The elevated CRS-R:L teacher rating of AD/HD symptoms criteria was waived if the 
teacher was unable to rate the child behavior when off-medication.  
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United Kingdom; however, due to the need for birth history data, only youth from 
Ireland, the Netherlands, and the United Kingdom were included in this study. Families 
participating in the IMAGE study had a child who: 1) was between the ages of 5-17 and 
met DSM-IV criteria for AD/HD combined type
3
; 2) had at least one full sibling between 
the ages of 5-17 available to participate in the study; and 3) had at least one biological 
parent available to participate in the study. Families were excluded from participating in 
IMAGE if the proband or sibling(s) had autism, epilepsy, an IQ < 70, or any genetic or 
medical disorder that could explain the presence of AD/HD symptoms based on clinical 
history.  
Prior to enrollment in IMAGE, all probands received clinical evaluations from a 
child psychiatrist or pediatrician. The presence of DSM-IV AD/HD was determined by 
combining parental responses on the Parental Account of Childhood Symptoms (PACS; 
Taylor, Sandberg, Thorley, & Giles, 1991), a semi-structured clinical interview, and 
teacher responses to DSM-IV AD/HD symptoms on the CRS-R:L (Conners, 1997). 
Parental qualitative responses to the PACS were matched to a quantitative and frequency 
severity score. Scores were then weighted and combined with an algorithm to map onto 
each AD/HD symptom. PACS symptom item scores were combined with teacher 
responses on the CRS-R:L using the “either rule” to determine AD/HD diagnostic status 
(Müller et al., 2011).   
                                                 
3
 Before quality control measures were implemented, some IMAGE participants met 
criteria for DSM-IV Predominantly Inattentive Type, DSM-IV Predominantly 
Hyperactive-Impulsive Type, or were one symptom short of a DSM-IV AD/HD 
diagnosis. These individuals were retained in analyses.  
 
32 
 
Of the 398 total participants in the current study, there were 360 probands and 38 
siblings. The sample had a mean age of 10.7 years (3.02) and was 83% male, which is 
consistent with the gender differences in AD/HD prevalence among clinical samples 
(APA, 2000). The sample was 100% Caucasian as genotype imputation procedures were 
based on a Caucasian reference group.  
The total sample consisted of 381 youth meeting criteria for AD/HD and 17 
unaffected youth. The current study had a higher percentage of individuals meeting 
criteria for AD/HD Combined Type (86%), and lower percentages of individuals meeting 
criteria for AD/HD Predominantly Inattentive Type (11%) and AD/HD Predominantly 
Hyperactive-Impulsive Type (3%) relative to prevalence rates of AD/HD subtypes in 
community (Dupaul, Power, Anastopoulos, & Reid, 1998; Gaub & Carlson, 1997) and 
AD/HD clinical samples (Lahey et al., 1994). In terms of AD/HD symptom count, the 
overall sample displayed an average of 7.97 (SD = 1.32) inattentive symptoms and 7.49 
(SD = 2.03) hyperactive-impulsive symptoms. In regard to developmental deviance, the 
average parent CRS-R:L AD/HD Total (M = 77.59, SD =10.45), DSM-IV Inattention (M 
= 71.98, SD = 10.12) and DSM-IV Hyperactivity-Impulsivity score (M = 78.73, SD 
=11.38) were all in the clinically significant range. Compared to the NCGAP subsample, 
the IMAGE subsample had a higher proportion of probands, χ
2 
(1, N = 398) = 90.91, p < 
.01, a higher proportion of males, χ
2 
(1, N = 398) = 18.62, p < .01, and was older, t (396) 
= -9.44, p < .01.  A summary of demographic variables appears in Table 2. Consistent 
with differences in ascertainment (i.e., focus on AD/HD Combined subtype in IMAGE), 
the IMAGE subsample had more severe AD/HD symptomatology than the NCGAP 
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subsample. For example, the IMAGE subsample had higher levels of both inattentive 
t(120) = -3.02, p < .01) and hyperactive-impulsive symptoms, t(104) = -7.31, p < .01). 
Furthermore, The IMAGE subsample had a higher parent CRS-R:L AD/HD DSM-IV 
Hyperactive-Impulsive score t(137) = -5.09, p < .01) and AD/HD Total Score t(135) = -
2.81, p = .006) than the NCGAP subsample. See Table 3 for additional AD/HD sample 
information.   
Consistent with previous findings in AD/HD clinical samples (Pfiffner et al., 
1999) many youth in the current study also met criteria for comorbid disorders, including 
oppositional defiant disorder (59.2%), conduct disorder (21.8%), mood disorder (18.0%), 
bipolar disorder (0.8%), anxiety disorder (41.3%), obsessive-compulsive disorder (4.8%), 
tic disorder (4.3%), and a substance abuse disorder (1.0%). The IMAGE sample had a 
significantly higher proportion of oppositional defiant disorder χ
2
(1, N = 395) = 35.53, p 
< .01, conduct disorder, χ
2
(1, N = 395) = 24.74 , p < .01, mood disorders, χ
2
(1, N = 395) 
= 17.27, p < .01, anxiety disorders, χ
2
(1, N = 395) = 47.06, p < .01, and obsessive-
compulsive disorder, χ
2
(1, N = 395) = 4.73, p = .03. Differences between samples are 
likely related to differences in NCGAP and IMAGE ascertainment and assessment 
procedures. See Table 4 for additional comorbidity information. 
In terms of birth characteristics, the samples’ mean birth weight (M = 3389.25 
grams or 7 lbs and 11 oz; SD = 565 grams or 1 lb and 4 oz) and gestational age (M = 
39.56 weeks; SD = 1.94 weeks) were in the normal range. Additional pregnancy, birth 
and delivery information is presented in Table 5. Note, however, that the supplementary 
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pregnancy, birth and delivery variables (e.g., infant needed oxygen) were not consistently 
or uniformly measured across sites and should be interpreted with caution. 
Measures -NCGAP Ascertainment 
 Computerized Diagnostic Interview Schedule for Children – IV Parent 
Version (C-DISC-IV; NIMH, 1997).  The C-DISC-IV is a computerized structured 
diagnostic interview that assesses a broad range of child and adolescent psychopathology 
based on current DSM-IV criteria.  A trained interviewer read each item to the parent, 
who provided a yes or no response indicating whether or not the item applies to their 
child.  The AD/HD module of the DISC-IV has adequate test-retest reliability in clinic 
samples (.79; Shaffer, Fisher, Lucas, Dulcan, & Schwab-Stone, 2000) and criterion 
validity (κ = .72) with clinician ratings (Schwab-Stone et al., 1996).  Parental responses 
to the C-DISC-IV AD/HD module were used by the diagnostic panel in determining the 
presence and absence of AD/HD and comorbid conditions of all youth participants.    
Conners’ Rating Scale-Revised Long Form (CRS-R:L; Conners, 1997). The 
CRSR:L measures a range of common child psychiatric factors, including DSM-IV 
AD/HD inattention and hyperactivity-impulsivity symptom dimensions.  Parents and 
teachers rated the extent to which each DSM-IV AD/HD symptom applied to their child 
on a scale from 0 (not at all true) to 3 (very much true), with higher ratings indicating 
greater AD/HD symptom severity.  The raw scores from the 9-item DSM-IV: AD/HD 
Inattention and the 9-item DSM-IV: Hyperactive-Impulsive scales were converted to T-
scores adjusting for age and gender of each participant (Conners, Sitarenios, Parker, & 
Epstein, 1998). A Conners’ Parent Rating Scale (CPRS) T-score ≥ 65 and Conners’ 
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Teacher Rating Scale (CTRS) T-score ≥ 60 on either the DSM-IV: Inattention or DSM: 
Hyperactive-Impulsive, were used as indicators of AD/HD symptom developmental 
deviance and cross-situational pervasiveness.  
 Clinical Global Impression Scale (CGI; Guy, 1976). The CGI is a standardized 
clinician rating scale used to measure the severity of an individual’s psychiatric disorder 
from 1 (normal, not ill) to 7 (among the most ill patients). The CGI was used as a severity 
measure of functional impairment related to AD/HD. Youth that were rated as ≥ 3 
(mildly ill) were eligible to be ascertained as NCGAP probands.  
Wechsler Intelligence Scale for Children – Fourth Edition (WISC-IV; 
Wechsler et al., 2004).  The WISC-IV is a standardized assessment of a youth’s current 
intellectual functioning.  A trained assessor administered the Block Design subtest, which 
is an indicator of perceptual reasoning, and Vocabulary subtest, which is a measure of 
verbal reasoning, to youth. The participant’s responses were scored and compared to a 
national sample of similar aged peers to derive an estimate of the participant’s current 
Intellectual Quotient (IQ). Youth were included in NCGAP with an estimated IQ  > 70.   
 Vineland Adaptive Behavior Rating Scale, Second Edition (Vineland-II; 
Sparrow et al., 2005). The Vineland-II survey interview measures the child’s current 
level of adaptive functioning in multiple domains including communication, daily living 
skills, socialization, and motor skills. A trained interviewer read each item to the youth’s 
parent and responses were coded, scored, and compared to an age-appropriate normative 
sample. The Vineland-II was only administered to parents of youth who had an estimated 
IQ between 70 and 80. Taken together with an estimated IQ between 70 and 80, an 
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Adaptive Behavior Composite score < 70 was used as exclusionary criteria in the 
NCGAP study. 
Pregnancy, delivery, and infant history. The NCGAP project obtained 
pregnancy, delivery and infant history through a developmental history form which was 
typically completed by participants’ mothers (See Appendix A). 
Measures-IMAGE Ascertainment 
 Parental Accounts of Childhood Symptoms (PACS; Taylor et al., 1991). The 
PACS is a standardized, semi-structured diagnostic interview that assesses for DSM-IV 
child and adolescent psychopathology, including AD/HD.  Child psychiatrists and 
clinical child psychologists trained in the administration of the PACS asked parents to 
rate the frequency and severity of their child’s behavior, across different situations. The 
interviewer then matched the parent’s responses to a behavior frequency or severity 
category which then were combined and weighted in an algorithm to indicate the 
presence or absence of corresponding DSM-IV symptoms.  Parental responses to the 
PACS were used, in part, to determine eligibility for inclusion in IMAGE, and to assess 
for DSM-IV AD/HD and other comorbid disorders.  
Conners’ Teacher Rating Scale (CRS-R:L; Conners, 1997). The DSM-IV 
AD/HD total subscale from the CTRS, maps onto the 18 DSM-IV AD/HD symptoms. 
Teacher symptom ratings of 2 (pretty much true) or 3 (very much true) were coded to 
indicate the presence of the AD/HD symptom. If either the PACS or CTRS indicated the 
presence of an AD/HD symptom, then the child was coded as having that symptom. This 
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process was used to determine if the participant met the symptom frequency criterion for 
AD/HD.  
Pregnancy, Delivery and Infant History Interview. IMAGE obtained 
pregnancy, delivery and infant history through developmental interviews which were 
then coded into the same categories found on the NCGAP developmental history form.  
GxE Measures 
Conners’ Parent Rating Scale (CRS-R:L; Conners, 1997).  Parent responses to 
the 18-item DSM-IV AD/HD total score were summed. The raw scores from the DSM-
IV AD/HD Total subscale were converted to T-scores adjusting for age and gender of 
each participant (Conners et al., 1998).  The resulting T-score was a continuous measure 
of AD/HD symptom severity and served as the outcome measure in this study.   
 Birth weight centile range. Birth weight centiles were calculated for each 
participant based on birth weight, gestational age and sex. Given that Dutch children tend 
to weigh heavier at birth compared to children with other ancestries (Troe et al., 2007), 
separate normative samples were used to calculate birth weight centiles for the 
Netherlands, United Kingdom/Ireland, and United States samples. In the current study, 
birth weight centile is a proxy measure for a restricted nutrient supply in utero and served 
as the environmental risk factor in the GxE model.   
IMAGE. For the Dutch sample, birth weight and gestational age (in weeks) were 
obtained through parent report. The Netherlands Perinatal Registry reference curves 
(Visser et al., 2009) were used to calculate birth weight centiles for the Dutch sample. 
The reference sample consists of 176,000 singleton births in the Netherlands during 2001. 
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The reference curves provide personalized centile ranges for individuals based on 
gestational age (in days), sex, ethnicity and parity. Gestational age to the day and parity 
were not available for individuals in the Dutch sample. Therefore, to offset the slight 
overestimation of birth weight centile related to using full week gestational age instead of 
gestational age in days, birth weight centiles were calculated using the multiparous 
normative sample, which only includes births from women who have delivered two or 
more babies.  Instead of providing individual centiles, the Netherlands Perinatal Registry 
reference curves (Visser et al., 2009) provide 11 normative references at 2.3, 5, 10, 16, 
20, 50, 80, 84, 90, 95, and 97.7 centiles. Therefore, 12 birth weight centile ranges were 
created (0-2.29, 2.3-4.9, 5-9.9, 10-15.9, 16-19.9, 20-49.9, 50-79.9, 80-83.9, 84-89.9, 90-
94.9, 95-97.6, 97.7 -100). Lower scores on the resulting ordinal severity scale of birth 
weight centile ranges represented higher levels of fetal growth compromise. 
Birth weight and gestational age for samples from Ireland and the UK were 
obtained from retrospective parent report.  The UK reference curves (Cole, Williams, & 
Wright, 2011) and Microsoft excel add-in (http://www.healthforallchildren.co.uk; Pan & 
Cole, 2010) were used to calculate birth weight centiles for the UK and Ireland samples, 
based on birth weight, gestational age (in weeks), and sex. The reference curves are based 
on 9,443 births in the UK between 1983-1993. For consistency, individual birth weight 
centiles were converted to birth weight centile ranges identical to those created in the 
Dutch sample.  
NCGAP. Birth weight and gestational age for the NCGAP sample was retrieved 
through medical records, parental report, and state birth registry with help from Marie 
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Lynn Miranda and Claire Osgood from the Children’s Environmental Health Initiative at 
Duke University.  Birth weight centiles for NCGAP were created using all singleton 
births from 2000-2004 from the CDC National Vital Statistics natality files 
(www.cdc.gov/nchs/data_access/Vitalstatsonline.htm).  Individual birth weight centiles 
were created using birth weight, week of gestational age and sex. For consistency, 
individual centiles were then converted to the centile ranges described above.   
Given that different methods were employed to assess birth weight and 
gestational age within and between sites, the level of agreement between parental recall 
and medical records of birth weight and gestational age was assessed. Consistent with 
previously reported associations between maternal recall and medical records (Hakim, 
Tielsch, & See, 1992; Rice et al., 2007) the level of agreement between birth records and 
maternal recall of birth weight in the NCGAP sample was high, intraclass correlation 
coefficient, ICC (76) = .99, p < .01. Similarly, the agreement between birth records and 
maternal recall of gestational age was also high, intraclass correlation coefficient, ICC 
(77) = .84, p < .01. 
Procedure 
NCGAP families were recruited to participate from: 1) two separate university 
AD/HD specialty clinics; 2) medical clinics in the community; 3) a community AD/HD 
parent support group; and 4) newspaper and magazine advertisements. Parents and youth 
from eligible families were scheduled for comprehensive psychological assessments, 
including structured diagnostic and semi-structured background interviews, self- and 
other-report ratings scales, and an intelligence assessment screening tool. All data were 
 
40 
 
collected by graduate-level research assistants or licensed psychologists trained to 
administer each measure. In addition, a phlebotomist collected blood samples of willing 
participants. All families received individualized research summary reports and $50 
dollars to compensate them for their travel and time. Out of nearly 400 youth who 
participated in NCGAP, 107 were included in the current study. Only participants that 
were Caucasian, genotyped using the Illumina Infinium HumanHap300 duo (Illumina, 
Inc., San Diego, CA), and had all necessary developmental and clinical data were 
included in the current study.  
IMAGE families were recruited from AD/HD specialty centers in 12 European 
and Asian nations. All participants underwent clinical evaluations including semi-
structured clinical interviews and parent- and teacher-rating scales. All evaluations were 
completed by pediatricians or child psychiatrists, and both existing and new clinic 
patients were enrolled in the study. The study was approved by the Institutional Review 
Board of each center which was registered with the National Institute of Health. Of the 
nearly 1,000 families participating in the IMAGE project, a subset of 291 youth were 
included in the current study.  Only youth from Ireland, the Netherlands, and the United 
Kingdom participated as birth history data were not collected at other IMAGE sites.    
Genotyping. SNP genotyping for the NCGAP subsample was performed using 
the Illumina Infinium HumanHap300 duo (Illumina, Inc., San Diego, CA). Two Centre 
d’Etude du Polymorphism Humain (CEPH) controls and blinded duplicates were used for 
every 94 samples and required to match 100%. Additional quality checks of the 
genotyping data were examined using PLINK (pgnu.mgh.harvard.edu/~purcell/plink; 
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Purcell et al., 2007). Call rates exceeded 98% for all individuals. Individuals were 
excluded due to gender discrepancy and if per-family Mendelian errors were in excess of 
1%.  SNPs were excluded from analysis if they had Mendelian errors in > 4 families or 
deviated from Hardy-Weinberg Equilibrium (HWE; p < 0.000001).  
 Genotyping for the IMAGE subsample was performed by Perlegen Sciences on a 
microarray designed for the Genetic Association Information Network (GAIN). Quality 
checks were completed by the National Center for Biotechnology Information (NCBI) 
using GAIN QA/QC (version 0.7.4) created by Goncalo Abecasis and Shyam 
Gopalakirshnana at the University of Michigan. GAIN QA/QC is available by emailing 
gopalakr@umich.edu or goncalo@umich.edu.  Individuals were excluded due to gender 
discrepancy and if per-family Mendelian errors were in excess of 2%. SNPs were 
excluded if the: 1) call rate was <  95%; 2) heterozygosity was > 32%; 3) genotype call 
quality score was > 10%; or 4) HWE p < 0.000001. 
SNPs within genes that encode for dopaminergic factors (i.e., COMT, DAT1, 
DRD2, DRD3, and DRD5), neurotrophic factors (i.e., BDNF, NGF, NT3, NGFR, 
NTRK2, and NTRK3) and angiogenic factors (VEGFA, VEGFR1, VEGFR2, NRP1, 
NRP2, HIF1A, and HIF1AN) that passed quality control measures were considered for 
inclusion in the GxE analysis.  In addition, SNPs from NTRK1, a neurotrophic family 
receptor, were intended to be included in this analysis; however, NTRK1 SNPs were 
unavailable. Therefore, SNPs from CD1B, a nearby gene, were included instead. CD1B 
is a member of the CD1 family of transmembrane glycoproteins and is slightly upstream 
from NTRK1 on chromosome 1.  
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In addition, SNPs that encode for growth factors (FGF1, FGF2, IGF1, IGF1R, IGF2, 
IGF2R, and NLN) were considered for inclusion in exploratory analyses.  
To increase coverage across candidate genes and to increase genotype overlap 
across NCGAP and IMAGE, genotype data were imputed with the use of the phased data 
from the HapMap samples (CEU; build 36, release 22) and MACH 
(http://www.sph.umich.edu/csg/abecasis/MaCH/download/; Li, Willer, Sanna, & 
Abecasis, 2009; Li, Willer, Ding, Scheet, & Abecasis, 2010). 
A total of 1349 dopaminergic, neurotrophic and angiogenic and 918 growth factor 
SNPs were submitted for quality checks. To reduce the number of statistical tests 
conducted, remaining SNPs with a minor allele frequency (MAF) < 0.2 or in linkage 
disequilibrium (LD; r
2 
≥ .64) were eliminated. If a SNP, however, was excluded due to 
LD and has demonstrated functional significance, as determined through F-SNP 
(http://compbio.cs.queensu.ca/F-SNP/; Lee & Shatkay, 2008), then it was retained. A 
total of six functional SNPs were retained (i.e., rs20541, rs4934838, rs2228638, 
rs7993418, rs6265, rs4633). After quality control and multiple testing reduction 
procedures were completed a total of 97 SNPs in dopaminergic, neurotrophic and 
angiogenic systems and 53 growth factor SNPS were retained for analysis.  
Data Analysis 
Bivariate correlations and Pearson product-moment correlation coefficients 
examined the direction, magnitude, and significance of the relationship between 
demographic, perinatal, and AD/HD variables. In addition, t-tests and ANOVAs were 
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conducted to test for differences between demographic groups on perinatal and AD/HD 
variables. Alpha was set at .01 for these analyses.  
Generalized Estimating Equations (GEEs) were conducted to test for main effects 
of SNP genotype and birth weight centile range, and the interaction between SNP and 
birth weight centile range in predicting AD/HD symptom severity.  GEEs extend 
generalized linear models to accommodate the analysis of clustered data (Hardin & 
Hilbe, 2003). Given that within family data are more correlated than between family data, 
GEEs account for the family correlation among siblings within the sample.  For the 
present study, family was the subject variable and the individual was the within subject 
variable in the GEEs.  An independent working correlation matrix was specified and the 
model-based robust estimator covariance matrix was selected, which provides a reliable 
covariance estimate even when the correlation matrix is not correctly specified. The 
CPRS AD/HD Total score was transformed to have normal skewness (described below) 
and served as the outcome variable for GEEs.  
Three separate sets of linear GEEs were run. First, to examine main effects of 
SNPs on ADHD severity, the main effects of site, age, and sex were entered into the 
model as covariates.  Next, the SNP main effect was entered into the model to test for 
effects of SNP genotype on AD/HD symptom severity.   
Second, to test the hypothesis that fetal growth compromise is associated with 
increased AD/HD symptom severity, the main effects of site, age, and sex were first 
entered into the model as covariates. Next, the main effect of birth weight centile range 
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was entered into the model to examine the association between birth weight centile range 
and AD/HD symptom severity. No SNP main effect was included in this model.  
Third, to test the hypothesis that fetal growth compromise moderates the 
relationship between SNP genotype and AD/HD symptom severity, the covariates of site, 
age, and sex were entered into the model. Next, the main effects of SNP genotype and 
birth weight centile range were entered into the model. Finally, the interaction of SNP 
and birth weight centile range was entered into the model.  
Wald chi-square tests calculated with Type III sums of squares tested the 
significance of main and interactive effects. In addition, continuous variables were 
centered to ease the interpretation of the direction of model effects. For comparison 
purposes, the above models were also conducted without site, age, and sex covariates.  
No genetic model (e.g., additive, dominant or recessive) was assumed in this analysis. 
In the GEEs, α was set at .05 for nominally significant findings. A total of 144 
independent GEEs were calculated. The Benjamini-Hochberg False Discovery Rate 
(FDR; Benjamini & Hochberg, 1995) test was used to adjust for multiple comparisons. 
The FDR q-value threshold was set at .05 to determine statistical significance.  
Given that birth size has a substantial heritability estimate, birth weight centile 
range was regressed onto growth factor SNPs to determine if birth weight centile range 
was correlated with SNPs within growth factor genes. Forward selection was used to 
enter SNPs into the stepwise regression model. SNPs were retained in the model if the 
contribution to R
2
 was significant at the .05 level. The birth weight centile range residual 
from the final model was retained. The residualized birth weight centile range variable 
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then replaced the non-residualized variable in GEEs containing nominally significant and 
significant interactions to examine if SNPs associated with fetal growth could account for 
the observed SNP x birth weight centile range interactions. All analyses were conducted 
in SPSS version 19.  
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CHAPTER III 
RESULTS 
 
Data Preparation 
To examine whether assumptions for GEEs were met, the predictor and response     
variables were inspected. The T-score of the CPRS AD/HD Total scale was non-normally 
distributed, with a skewness of -.81 (SE = .122) and kurtosis of 1.38 (SE = .24). Separate 
data transformations were applied to normalize the skewed distribution. The square root 
of the reflected T-score (e.g.,      ), where K is a constant and equals the highest 
score + 1, resulted in the most normally distributed CPRS AD/HD Total score variable, 
skewness = -.03 (SE = .122), kurtosis = 1.30 (SE = 2.44) and was retained for analysis. 
Skewness for all other variables included in GEEs was in the normal range; thus, no other 
variables were transformed.  The non-transformed CPRS AD/HD Total score was 
retained in some analyses for interpretative purposes. In such cases, results were 
synonymous with the same analysis using the transformed CPRS AD/HD Total score 
variable. 
Demographic and AD/HD Variables 
 Older youth tended to have higher CPRS AD/HD Total (r = .21; p < .01), DSM-
IV: Inattentive (r = .13; p < .01), and DSM-IV: Hyperactive-Impulsive scores (r = .25; p 
< .01). On average, CPRS AD/HD Total scores were higher for females (M = 81.23) than 
males (M = 76.82), t(79.36) = 2.39, p = .02, at a trend level. CPRS AD/HD Total scores 
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also varied across data collection sites, F(5, 397) = 4.09, p < .01. In general, IMAGE 
samples had higher CPRS AD/HD Total scores compared to the NCGAP samples (Duke, 
M = 74.24, SD = 13.96; UNCG, M = 75.19, SD = 14.49; Ireland, M = 79.27, SD = 9.26; 
Netherlands-Amsterdam, M = 76.35, SD = 8.22; Netherlands – Nijmegen, M = 78.32, SD 
= 7.82; UK, M = 81.58; SD = 8.33).  
Demographic, Perinatal, and AD/HD Variables 
 Older participants tended to have lower birth weight centile range scores (r = -.14; 
p < .01). Birth weight was associated with increased birth weight centile range (r = .755; 
p < .01) and increased gestational age (r = .50; p < .01). In addition, maternal smoking 
during pregnancy was associated with paternal smoking during pregnancy (r = .72; p < 
.01) and increased maternal alcohol use during pregnancy (r = .11; p = .03) at a trend 
level. See Table 6 for additional correlations between selected demographic, perinatal 
variables and CPRS AD/HD Total score. 
There were no differences between males and females in birth weight centile 
range t(396) = .67, p = .50, birth weight t(396) = .-.707, p = .48, and gestational age 
t(396) = .72, p = .47. Birth weight centile range scores, however, varied across data 
collection sites, F(5, 397) = 8.34, p < .01 (Duke, M = 6.92, SD = .28; UNCG, M = 7.98, 
SD = .34; Ireland, M = 6.26, SD = .24; Netherlands – Amsterdam, M = 5.77, SD = .22; 
Netherlands – Nijmegen, M = 5.88, SD = .26; UK, M = 7.24, SD = .39).  
Generalized Estimating Equations (GEEs) 
  GEEs were used to examine the main effects of SNPs and birth weight centile 
range, and the interaction effects of SNP x birth weight centile range on AD/HD 
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symptom severity. Each analysis controlled for family correlation. In addition, although 
the primary analysis controlled for research site, age at assessment, and sex, separate 
analyses were also conducted that did not control for covariates for exploratory purposes.  
Generally, including age, sex and research site as covariates in GEEs did not have a 
substantial impact on the results. Therefore, only results from the primary analysis 
including research site, age and sex covariates are summarized below.   
Main effects of SNPs on AD/HD symptom severity. Out of the 97 SNPs entered 
into the independent GEEs, after controlling for site, age, and sex, a total of 8 SNPs had a 
nominally significant main effect on AD/HD symptom severity (see Table 7). In the 
dopamine system, rs456774 (Wald = 6.67; p < .05) in DAT1 was associated with AD/HD 
Total Score. In the neurotrophic system, rs7127507 (Wald = 7.34; p = .03) and rs6265 
(Wald = 6.82; p = .03) in BDNF, rs3825885 (Wald = 9.30; p = .01) and rs999905 (Wald 
= 6.67; p = .04) in NTRK3, and rs10780796 (Wald = 6.23; p = .04) in NTRK2 were 
associated with AD/HD Total score. In the angiogenic system, rs2104330 (Wald = 7.90; 
p = .02) in VEGFR1 and rs10016788 (Wald = 7.59; p = .02) in VEGFR2 were also 
associated with AD/HD Total score. See Table 8 for a summary of these comparisons.  
No SNP main effects remained significant after multiple testing corrections. 
Main effect of birth weight centile range on AD/HD symptom severity. 
Contrary to hypotheses, birth weight centile range was not associated with the 
transformed AD/HD Total score in either the covariate (b = -.023, SE = .0198; p = .243) 
or no covariate models (b = -.012, SE = .020; p = .547).   
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Interactions between SNPs and birth weight centile range on AD/HD 
symptom severity. Out of the 97 SNP x birth weight centile range interactions tested, 
there were 8 nominally significant interactions in the covariate model (see Table 7). Birth 
weight centile range moderated associations between SNPs within angiogenic (i.e., 
NRP1, NRP2, and VEGFR1) and neurotrophic genes (i.e., NTRK2 and NTRK3) and 
AD/HD Total score.  In the angiogenic system, birth weight centile range moderated 
associations between rs9513089 (VEGFR1, Wald = 6.59, p = .04), rs2065364 (NRP1, 
Wald = 8.05, p = .02), rs734187 (NRP1, Wald = 6.21, p < .05), rs17682318 (NRP2, Wald 
= 8.27, p = .02), rs10932118 (NRP2, Wald = 7.63, p = .02), and rs12611613 (NRP2, 
Wald = 6.53, p = .04) and AD/HD Total Score. In the neurotrophic system, birth weight 
centile range moderated associations between rs11141486 (NTRK2, Wald = 8.92, p = 
.01) and rs8031510 (NTRK2, Wald = 6.71, p = .04) and AD/HD Total score.  Nominally 
significant interactions appear in Figures 2 and 3.  Birth weight centile range did not 
moderate the relationship between SNPs within dopamine genes and the AD/HD Total 
score.  No interactions remained significant after accounting for multiple testing.  
Reexamining nominally significant interactions after statistically controlling 
for SNPs associated with fetal growth. Given that fetal growth has a substantial 
heritability estimate, the correlation between SNPs within candidate genes associated 
with fetal growth was removed from the birth weight centile range variable. Note that 
these SNPs are within genes that encode for factors associated with fetal growth (Baker, 
Liu, Robertson, & Efstratiadis, 1993; Hill, Petrik, & Arany, 1998) and are not within the 
angiogenic, neurotrophin, or dopaminergic systems.  
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Birth weight centile range was regressed onto 53 SNPs within candidate genes 
associated with fetal growth (i.e., FGF1, FGF2, IGF1, IGF1R, IGF2, IGF2R, and NLN) 
using a forward selection method. The final model, F(3,306) = 6.23, p< .01, included 
three SNPs within IGF2R (rs4709391) and FGF1 (rs4912870 and rs12523052), and 
accounted for a small proportion of birth weight centile range variance (adjusted R
2
 = 
.048). Compared to the original birth weight centile range variable, the residualized birth 
weight centile range is presumably less heritable. Thus, the residualized birth weight 
centile range variable was included for these GEEs. Residualized birth weight centile 
range moderated the association between 6 of the 8 previously reported nominally 
significant interactions including the following SNPs (rs17682318, NRP2, Wald = 8.54, p 
= .014; rs10932118, NRP2, Wald = 8.48, p = .014; rs11141486, NTRK2, Wald = 7.15,p 
= .028; rs12611613, NRP2, Wald = 6.57, p = .037; rs734187, NRP1, Wald = 6.07, p = 
.048; rs9513089, NRP2, Wald = 6.03, p = .049). When using the residualized birth 
weight centile range variable, two interactions were no longer nominally significant 
(rs8031510, NTRK3, Wald = 5.41, p = .067; rs2065364, NRP1, Wald = 4.97, p = .083).  
Exploratory analyses: Interactions between less prevalent SNPs and birth 
weight centile range on AD/HD symptom severity. Given that the above analyses 
focused on SNPs with more common minor allele frequencies, many SNPs within the 
candidate systems of interest were not examined. Therefore, to expand coverage across 
candidate systems of interest the minor allele frequency criterion was reduced from .20 to 
.10 for exploratory analyses. Other inclusion and exclusion criteria remained the same 
(see page 44) and were reapplied to develop a new list of unique SNPs within candidate 
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systems of interest (i.e., angiogenic, dopaminergic, and neurotrophic pathways). An 
additional 47 SNPs were identified for this analysis. Out of the 47 additional SNPs 
examined, 7 SNPs had nominally significant main effects on the AD/HD Total score. 
Nominally significant SNPs were within angiogenic, dopamine, and neurotrophic genes.  
In the angiogenic pathway, variants within NRP1 (rs2776930, Wald = 25.76, p <.01; 
rs2474712, Wald = 7.59, p = .02) were associated with AD/HD Total score. In the 
dopaminergic pathway, SNPs within COMT (rs9332377, Wald = 99.87, p < .05), DRD2 
(rs4350392, Wald = 7.96, p = .02), and DRD3 (rs324035, Wald = 13.79, p < .01) were 
associated with AD/HD Total score. Lastly in the neurotrophic pathway, two SNPs 
within NTRK3 (rs8037291, Wald = 7.92, p = .02; rs7176444, Wald = 6.28, p = .04) were 
associated with AD/HD Total score. See Table 8 for a summary of these comparisons. 
In addition, birth weight centile range moderated the association between 12 
SNPs and the AD/HD Total score. Nominally significant interactions included SNPs 
within angiogenic (HIF1A and NRP1) and neurotrophic genes (NTRK3) and CD1B. 
Furthermore, six SNP x birth weight centile range interactions survived multiple testing 
corrections. In the angiogenic pathway, birth weight centile range moderated the 
relationship between SNPs in HIF1A (rs2057482, Wald = 113.70, q < .05; rs2301106, 
Wald = 124.39, q < .05) and NRP1 (rs11598845, Wald = 29.47, q < .05) and AD/HD 
Total score. In the neurotrophic pathway, birth weight centile range moderated the 
relationship between SNPS within NTRK3 (rs71764444, Wald = 45.21, q < .05; 
rs8037291, Wald = 16.26, q < .05) and AD/HD Total score. Finally, birth weight centile 
range moderated the association between a SNP in CDIB (rs962879, Wald = 25.53, q < 
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.05) and AD/HD Total score.  Generally, compared to other genotypes, homozygotes for 
the minor allele had increased AD/HD Total scores as birth weight centile range 
decreased. A summary of results from these analyses is presented in Table 9. Interactions 
with q-values < .05 appear in Figure 4.    
Reexamining significant interactions after statistically controlling for SNPs 
associated with fetal growth. A residualized birth weight centile range variable was 
created to account for the relationship between SNPs within fetal growth candidate genes 
and fetal growth. Birth weight centile range was regressed onto 73 SNPs within FGF1, 
FGF2, IGF1, IGF1R, IGF2, IGF2R, and NLN using step-wise forward selection. These 
SNPs are not within angiogenic, neurotrophin, or dopaminergic systems, but rather are 
associated with fetal growth. SNPs associated with fetal growth were identified using the 
same criteria as before; however, the minor allele frequency criterion was reduced to .10. 
Only rs11111272 in IGF1 entered into the model, F(3,306) = 6.23, p < .01, and the 
adjusted R
2
 = .011. To reinvestigate statistically significant interactions, the residualized 
birth weight centile range variable replaced birth weight centile range in the GEEs.  All 
interactions remained significant (p < .001). This may suggest that SNPs within fetal 
growth candidate cannot account for the observed interactions between SNPs within 
angiogenic and neurotrophic genes and AD/HD Total score. 
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CHAPTER IV 
DISCUSSION 
 
Behavioral genetic studies demonstrate that genetic factors are paramount in the 
etiology of AD/HD (Faraone et al., 2005); however, molecular genetic studies have 
uncovered only a small proportion of AD/HD’s heritability estimate (Nigg, 2006).  GxE 
may be a main contributor to AD/HD’s hidden heritability, yet there has been a relative 
lack of AD/HD GxE research.  To date, AD/HD GxE research has focused on genes that 
have demonstrated associations with AD/HD and encode for factors associated with 
neurotransmission, especially dopamine. This approach has produced mixed findings 
(Nigg et al., 2010) and studies rarely provide a rationale for why a given environmental 
risk factor would moderate the association between a selected candidate gene and 
AD/HD.   
Out of many environmental risk factors associated with AD/HD, birth weight 
centile, or fetal growth compromise is well-suited for inclusion in GxE research as it: 1) 
has a well-established association with AD/HD (Nigg et al., 2010) which cannot be 
accounted for by genetic factors (Lehn et al., 2007; Sharp et al., 2003); 2) is associated 
with neurodevelopmental risk for AD/HD (Brown et al., 2009; Peterson et al., 2003; 
Tolsa et al., 2004); 3) is a measure of cumulative prenatal environment risk (Kramer, 
1987) which restricts nutrient supply in utero; and 4) can be reliably measured (Tomeo et 
al., 1999). Although the association between fetal growth compromise and AD/HD is 
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well-established, little is known about how fetal growth compromise moderates the 
relationship between genetic risk and AD/HD.  
GWAS in AD/HD have helped to broaden our understanding of AD/HD’s genetic 
origins. Findings suggest that genes implicated in basic neurodevelopmental processes 
(Franke et al., 2009; Poelmans et al., 2011) are associated with vulnerability for the 
disorder. Angiogenic, dopaminergic, and neurotrophic systems have all been implicated 
in the pathophysiology of AD/HD and are regulated by a restricted nutrient supply in 
utero. From a DOHaD framework (Gluckman & Hanson, 2004), angiogenic, 
dopaminergic and neurotrophic factor response to a restricted nutrient supply in utero 
may modify vulnerability for AD/HD.  Therefore, this study examined whether fetal 
growth compromise moderated associations between SNPs within angiogenic, 
dopaminergic, and neurotrophic genes and AD/HD symptom severity.  
Hypotheses  
 Contrary to the first hypothesis, fetal growth compromise was not associated with 
increased AD/HD symptom severity. In general, the literature demonstrates that fetal 
growth compromise is associated with increased AD/HD symptom severity; however, 
this finding may vary with sample composition. Research with community samples that 
exhibit the entire spectrum of AD/HD symptom severity have shown that LBW, birth 
weight adjusted for gestational age, and ponderal index are associated with increased risk 
for AD/HD (Bhutta, Cleves, Casey, Cradock, & Anand, 2002; Indredavik et al., 2004; 
Lahti et al., 2006). In contrast, AD/HD clinical samples have not demonstrated a 
relationship between fetal growth compromise and AD/HD symptom severity (e.g., 
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Langley et al., 2007). The reduced variability in AD/HD symptom severity in case-only 
or family-based designs may make the relationship between fetal growth and AD/HD 
difficult to detect. In the absence of a main effect of fetal growth compromise on AD/HD, 
it is still appropriate to examine for interactions as fetal growth compromise may 
moderate the relationship between genotype and AD/HD. 
In partial support of the second hypothesis, fetal growth compromise moderated 
the relationship between SNPs within angiogenic and neurotrophic genes, but not 
dopamine genes, and AD/HD symptom severity. A total of six separate SNP x birth 
weight centile range interactions were associated with AD/HD. In the observed 
interactions, homozygosity for the minor allele tended to be associated with higher levels 
of AD/HD symptom severity, especially at low birth weight centile range scores. All 
significant interactions were observed for SNPs with minor allele frequencies below .20, 
suggesting that less common variants in angiogenic and neurotrophic genes may play a 
role in the etiology of AD/HD. 
These findings suggest that angiogenic and neurotrophic factor response to a 
restricted nutrient supply in utero may be associated with vulnerability for AD/HD.  
These findings are consistent with research that demonstrates a restricted nutrient supply 
in utero moderates the expression of genes within angiogenic (Jaakkola et al., 2001; Mac 
Gabhann & Popel, 2008) and neurotrophic systems (Cannon et al., 2008; Schmidt-
Kastner et al., 2001). Together these findings suggest that ischemia/hypoxia regulated 
variants in angiogenic and neurotrophic pathways interact with a restricted nutrient 
supply in utero to confer risk for AD/HD.  Interestingly, fetal growth compromise did not 
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moderate the association between SNPs within dopamine genes and AD/HD symptom 
severity. Although ischemia/hypoxia alters dopaminergic transmission, this change seems 
to relate to factors that are more directly involved with adaptation to hypoxia, such as 
HIF1 (Johansen et al., 2010).   
 In the angiogenic pathway, fetal growth compromise moderates relationships 
between SNPs within HIF1A and NRP1 and AD/HD, which to date has not been reported 
in the literature. HIF1A is located on chromosome 14q23.2 and encodes for the alpha 
subunit of hypoxia-inducible factor 1 (HIF1α). HIF1α is necessary for normal embryonic 
(Yu et al., 1999), vascular and neural development (Tomita et al., 2003). HIF1α is a 
primary regulator of the cellular response to hypoxia (Sharp & Bernaudin, 2004) and 
accumulates in cells during hypoxic conditions (Chávez, Agani, Pichiule, & Lamanna, 
2000). HIF1α typically helps organisms adapt to hypoxic conditions by regulating the 
transcription of a broad range of target genes (Sharp & Bernaudin, 2004) which confer 
neurological and vascular adaptation (Schmidt-Kastner et al., 2006; Sharp & Bernaudin, 
2004).  In fact, the two HIF1A SNPs (rs2057482 and rs2301106) which interacted with 
fetal growth compromise to predict AD/HD symptom severity may be related to HIF1A 
transcriptional regulation (see Table 10).  
Although HIF1α mediates neural and vascular adaptation during prenatal 
development, increasing cell survival in the moment may lead to increased risk for 
neurodevelopmental and neurodegenerative disorders in later development (Schmidt-
Kastner et al., 2006; Sharp & Bernaudin, 2004). For example, HIF1α confers hypoxic 
induced protection against future hypoxia, which relates to DNA damage and repair in 
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cells exposed to hypoxia (Englander, Greeley, Wang, Perez-Polo, & Lee, 1999). From a 
DOHaD perspective, HIF1α increases cell survival when exposed to prenatal hypoxia; 
however, the resulting DNA repair response may leave the organism ill prepared to 
function effectively in postnatal environments with normal oxygen concentration.  
Given that hypoxia moderates the expression of HIF1α, and birth weight and 
hypoxia covary (Apel-Sarid, Levy, Holcberg, & Sheiner, 2010), prenatal hypoxia may be 
moderating the relationship between HIF1A and AD/HD in nature. Prenatal hypoxia has 
been shown to be associated with AD/HD (Ben Amor et al., 2005; Pineda et al., 2007); 
however, it has received little attention in the AD/HD literature.  
NRP1 is located on chromosome 10p12 and encodes for a neuropilin-1, a receptor 
for VEGF-A (Shibuya, 2008) and semaphorin-3A (He & Tessier-Lavigne, 1997). 
Neuropililin-1 is expressed in the central nervous system, endothelial (Gu et al., 2003) 
and tumor cells (Chen et al., 2005) and plays an essential role in vascular development 
and axonal guidance (Gu et al., 2003; Polleux, Morrow, & Ghosh, 2000). NRP1 plays a 
central role coordinating neuronal migration and guidance of axons that project from the 
thalamus to the cortex (López-Bendito et al., 2006). Interestingly, these neural pathways 
are implicated in the pathophysiology of AD/HD (Sagvolden et al., 2005). Previous 
AD/HD genetic research has also implicated genes involved in neuronal migration in the 
etiology of the disorder (Franke et al., 2009). Similar to HIF1α, NRP1 is upregulated 
during prenatal ischemia which in turn disrupts axonal guidance near the ischemic area 
(Hou et al., 2008).  Together, this may suggest that disrupted neuronal migration may be 
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one route to AD/HD in those exposed to prenatal ischemia/hypoxia and who exhibit 
vulnerable NRP1 genotypes.  
In the neurotrophic pathway, fetal growth compromise moderated the relationship 
between SNPs within NTRK3 and AD/HD symptom severity. NTRK3 encodes for TrkC, 
a tropomyosin-related kinase receptor. TrkC is expressed throughout the brain, and is 
most abundant in the hippocampus (Ernfors, Merlio, & Persson, 1992).  Neurotrophin-3 
(NT-3) binds to TrkC and TrkA (Lamballe, Klein, & Barbacid, 1991), which promotes 
neuron survival and synaptic plasticity (Reichardt, 2006).  NTRK3 has not been 
associated with AD/HD by molecular genetic studies; however, NT3 has been associated 
with AD/HD (Ribasés et al., 2008).  Ischemia upregulates TrkC receptors in neurons and 
microglia (Lin et al., 2006). In addition, TrkC receptors are reduced in the dorsolateral 
prefrontal cortex of individuals with schizophrenia (Weickert et al., 2005). The 
dorsolateral prefrontal cortex is also implicated in the pathophysiology of AD/HD 
(Sagvolden et al., 2005). Together these findings may suggest that when exposed to 
prenatal ischemia/hypoxia, individuals with vulnerable NTRK3 variants may experience 
impaired functioning in the hippocampus and dorsolateral prefrontal cortex which 
increases AD/HD vulnerability. 
Fetal growth compromise was not predicted to moderate the association between 
CD1B SNPs (i.e., rs962879) and AD/HD symptom severity. There is no existing 
literature on the relationship between CD1B and fetal growth compromise or AD/HD; 
thus, it is difficult to explain why CD1B may be functionally related to AD/HD. This 
relationship may be due to rs962879 being in LD with a functional variant in another 
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gene.  As mentioned previously NTRK1 is also located on chromosome 1; however, it is 
unlikely to account for this relationship as NTRK1 is approximately 1.45 mega base pairs 
upstream from CD1B. Thus, other nearby variants may be playing a role. Alternatively 
this unhypothesized result may be a false positive.  
 With the exception of CD1B, genes involved in the significant interactions are 
regulated, in part, by ischemia/hypoxia. This may suggest that prenatal ischemia/hypoxia 
is an environmental pathogen underlying the relationship between fetal growth 
compromise and AD/HD. If true, the observed SNP x fetal growth compromise 
interactions are likely mediated by epigenetic processes, such as transcriptional 
regulation, which alter the expression of ischemia/hypoxia regulated angiogenic and 
neurotrophic genes. Individual variability in the expression of angiogenic and 
neurotrophic genes may then be associated with vulnerability for AD/HD (see Figure 5). 
From a DOHaD perspective, in response to prenatal ischemia/hypoxia, individual 
variability in angiogenic or neurotrophic gene expression may confer vulnerability for 
AD/HD in multiple ways. First, insufficient angiogenic or neurotrophic factor response to 
prenatal ischemia/hypoxia may lead to disrupted cerebral vascular or neural development 
and increase vulnerability for AD/HD. Second, if angiogenic and neurotrophic factor 
response to prenatal ischemia/hypoxia is adequate to promote neural and vascular 
endothelial cell survival, increased risk for future neurodevelopmental problems may 
arise from the surviving cells repair response to DNA damage (Sharp & Bernaudin, 
2004). In addition, early cerebral vascular adaptation to prenatal ischemia/hypoxia may 
constrain an individual’s ability to increase cerebral blood flow during demanding 
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environmental conditions (Fu & Olofsson, 2006).  Therefore, epigenetic processes that 
upregulate angiogenic and neurotrophic factors in response to prenatal ischemia/hypoxia 
may not always be associated with decreased vulnerability for AD/HD. Taken together, 
angiogenic and neurotrophic factor response to prenatal ischemia/hypoxia may confer 
vulnerability for AD/HD through developmental disruption, predicted adaptive responses, 
or constrained developmental plasticity.   
 This model helps to link previous AD/HD molecular genetic (Franke et al., 2009; 
Poelmans et al., 2011) and environmental research (Banerjee et al., 2007) which suggest 
that multiple neurodevelopmental factors are implicated in the pathophysiology of the 
disorder. For example, this study found that fetal growth compromise moderates the 
association between NRP1 (which is implicated in neuronal migration) and AD/HD. This 
fits with Poelmans et al. (2011) who found that disrupted axon guidance may be a 
common neurodevelopmental pathway to AD/HD. This suggests that to elucidate 
neurodevelopmental pathway to AD/HD, research should examine the interplay between 
environmental factors and genes that are: 1) functionally related; and 2) associated with 
more basic neurodevelopmental processes.    
Although hypodopaminergic functioning in prefrontal and limbic brain regions 
may be associated with many AD/HD cases (Levy, 1991), this study did not provide 
evidence that fetal growth compromise moderated the relationship between dopaminergic 
factors and AD/HD.  This suggests that although hypodopaminergic functioning may be a 
primary contributor to the pathophysiology of ADHD it is not necessarily the root cause 
of ADHD, for all individuals.  Instead, these findings suggest that hypodopaminergic 
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functioning: 1) may result from more basic neurodevelopmental delays or disruptions 
(e.g., disrupted axonal guidance); or 2) is not necessarily implicated in AD/HD’s 
pathophysiology, especially for individuals who develop AD/HD after experiencing 
prenatal ischemia/hypoxia. Taken together, these findings suggest that multiple 
developmental pathways to ADHD exist, which originate from the interplay between a 
broad range of genetic and environmental factors. This interplay confers vulnerability for 
ADHD by altering basic neurodevelopmental processes which may or may not give way 
to hypodopaminergic functioning.   
Limitations 
The findings of this study are promising but need to be considered in light of 
study limitations. First, youth in the study were either diagnosed with AD/HD or at 
genetic risk for AD/HD. This resulted in constrained variability in the primary outcome 
variable, AD/HD symptom severity. Constrained variability in  outcome measures 
reduces statistical power and the likelihood of significant findings. In addition, the 
average AD/HD symptom severity score was approximately 2.5 standard deviations 
above the population mean. Although etiological factors would be expected to exert 
similar influence on AD/HD throughout severity levels (Levy et al., 1997), the main and 
interactive effects in this study were observed in individuals with high levels of AD/HD 
symptoms. Therefore, it is unclear how findings would generalize to individuals with low 
to moderate levels of AD/HD symptom severity.     
On a related note, given that AD/HD symptoms vary across context, a multi-
informant approach to measuring AD/HD symptom severity is generally preferred, but 
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was not utilized in this study. Given that ADHD symptoms vary across context 
(Anastopoulos & Shelton, 2001), it is important to get multiple raters of youth’s 
behavior.AD/HD symptom severity was measured using a parent-report rating scale for 
consistency across sites and to maximize sample size.  In addition, inattention and 
hyperactive-impulsive symptoms were combined as a measure of overall AD/HD 
symptom severity, to reduce multiple testing. Although inattentive and hyperactive-
impulsive symptom dimensions share similar etiologies (McLoughlin, Ronald, Kuntsi, 
Asherson, & Plomin, 2007), each symptom dimension also has unique genetic and 
environmental risk factors (Nikolas & Burt, 2010; Smith, 2010).  
Birth weight centile range served as a proxy measure for nutrient supply in utero 
as no direct measure of nutrient supply in utero was available. Therefore, inferences 
about the underlying environmental pathogen were made in this study. Furthermore, birth 
weight has a substantial heritability estimate and it is not completely clear if identified 
interactions reflect gene-environment interplay and/or epistasis. To limit the probability 
of epistasis, SNPs within candidate fetal growth genes were controlled for in the 
analyses; however, other genetic factors may have played a role.  
Next, this analysis combined participants from NCGAP and IMAGE.  NCGAP 
and IMAGE had different approaches to ascertainment, genotyping, and assessment of 
fetal growth. These differences likely contributed to the many demographic, prenatal and 
phenotypic differences between the samples. In addition, the inclusion of the IMAGE 
Dutch sample required the use of birth weight centile range scores. This in turn 
complicated the interpretation of main and interaction effects involving birth weight 
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centile range. Research site was included as a covariate in the analyses to reduce the 
impact of site differences on the observed findings. Despite complications related to 
combining samples, this analysis was able to provide evidence that fetal growth 
compromise moderates associations between candidate system SNPs and AD/HD. Such 
findings may have been obscured in a smaller, more homogeneous sample.  
When conducting inferential statistical tests there is always a possibility of false 
positive findings. This study conducted 144 separate GxE interactions and utilized FDR 
to correct for multiple testing. FDR was chosen to preserve power; however, this 
approach is less conservative than other multiple testing corrections.  Furthermore, many 
steps were taken to reduce the number of statistical tests conducted, including removing 
SNPs that were in LD (r
2 
≥ .64). Although LD SNP exclusion reduced the number of 
statistical tests conducted, this may have resulted in excluding SNPs that interacted with 
fetal growth compromise to modify vulnerability for AD/HD.  
Due to imputation procedures, samples in psychiatric genetic studies are often 
racially homogenous. Pooling together samples from multiple sites, including North 
Carolina, Ireland, the Netherlands, and United Kingdom, allowed for European ancestral 
diversity within the sample. Due to genotyping procedures, however, this sample was 
100% Caucasian. This limits the generalizability of findings to other racial groups. Given 
that Caucasian race and access to prenatal care is a protective factor for fetal growth 
(Kramer, 1987), it is unclear how these findings would generalize to individuals of 
different races or individuals who do not have access to prenatal medical care.  
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 Lastly, the design of this study was unable to rule-out the effect of maternal 
genotype on the observed SNP x birth weight centile range interactions (see Waldman, 
2007). In light of the role of maternal angiogenic genotype in prenatal ischemia/hypoxia 
(e.g., Nakamura, Okamoto, Nagaya, & Hayashi, 2011), future research should include 
both maternal and child genotype in etiological models of AD/HD.  
Clinical and Public Health Implications 
 Bearing these limitations in mind, the results of this study have implications for 
AD/HD assessment and intervention. In terms of assessment, this study supports the 
notion that AD/HD reflects a continuous trait and that vulnerability for AD/HD is best 
conceptualized on a spectrum (Levy et al., 1997).  For etiological and prognostic 
considerations (e.g., Molina & Pelham, 2003). 2003), it is important to not only assesses 
the presence of AD/HD as a category, but also assess the severity of AD/HD 
symptomatology.  Consistent with this notion, Lahey and Willcutt (2010) suggest that 
DSM-V move towards using continuous symptom counts as diagnostic modifiers for 
AD/HD. For example, compared to AD/HD subtypes, symptom counts are better 
predictors of future functional impairment (Lahey & Willcutt, 2010). 
In terms of intervention, LBW is a well-established environmental risk factor for 
AD/HD (Nigg et al., 2010).  Therefore, it has been argued that reducing the incidence of 
LBW would lead to a modest reduction in the prevalence of AD/HD (Mick et al., 2002; 
Nigg, 2006). Unfortunately, reducing the incidence of LBW has proven difficult in both 
developing and developed nations (United Nations Children's Fund, 2004). Another 
approach to decreasing AD/HD risk for individuals who experience fetal growth 
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compromise is to identify malleable epigenetic and environmental factors that mediate 
the relationship between fetal growth compromise and AD/HD. Findings from this study 
may suggest that prenatal ischemia/hypoxia modifies the expression of angiogenic and 
neurotrophic genes, which in turn influences vulnerability for AD/HD. If true, targeting 
epigenetic mechanisms that are regulated by prenatal ischemia/hypoxia would provide an 
opportunity to improve neurodevelopment and decrease AD/HD risk in the face of 
prenatal ischemia/hypoxia. For example, interventions that increase the availability of 
HIF1 may help to protect individuals from prenatal ischemia/hypoxia (Bergeron et al., 
2000) and reduce risk for AD/HD and other neurodevelopmental disorders. Other 
research suggests that postnatal factors such as maternal warmth may also help to protect 
LBW youth from AD/HD (Tully, Arseneault, Caspi, Moffitt, & Morgan, 2004).  
Research Implications 
 This study provides support for candidate pathway approaches to genetic 
research, especially for studies with modest sample sizes. Candidate pathway GxE 
interaction studies are theoretically driven, and balance the importance of examining 
multiple genes that are related to the environmental risk factor and limiting the number of 
statistical tests. Future GxE studies may look to utilize the candidate pathway approach to 
manage these competing demands.  
 In addition, this study identified multiple genetic variants that are associated with 
AD/HD and many which have not been previously reported. This suggests that in order to 
elucidate AD/HD vulnerability genes, it is important to investigate GxE, as some genetic 
variants may only increase risk for the disorder in the presence of an environmental 
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factor. Including environmental factors in AD/HD genetic research may help to uncover 
more of AD/HD’s heritability estimate.  Furthermore, although dopaminergic genes have 
shown to be reliably associated with AD/HD (Gizer et al., 2009), fetal growth 
compromise only moderated associations between SNPs within angiogenic and 
neurotrophic genes and AD/HD. This suggests that the selection of candidate genes for 
GxE studies should be based on their relationship with the environmental pathogen 
(Moffitt et al., 2006) rather than the disorder of interest. This is one explanation for the 
varied findings in the AD/HD GxE literature, as candidate gene selection seems to be 
based on a genes association with AD/HD. 
Future Directions  
 It is important to replicate the promising findings from this study to further the 
search for malleable mechanisms linking birth weight with AD/HD. In particular, 
replication studies may include racially diverse and population-based samples. The 
majority of replication efforts in GxE studies in psychiatry fail (Duncan & Keller, 2011); 
however, the odds of positive replication may be greater for this study compared to the 
extant literature. For example, following recommendations from Moffitt and colleagues 
(2006), this study started with a well-established environmental risk factor for AD/HD 
(Nigg et al., 2010). Additionally, candidate gene pathways were selected based on their 
association with a restricted nutrient supply in utero, the DOHaD hypothesis, and 
relevance to AD/HD. This is in contrast to many other GxE studies that provide little 
rationale for predicting the presence of a GxE. In addition, following recommendations 
from Waldman (2007), attention was paid to the heritability estimate of birth weight. 
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Variants within birth weight candidate genes were statistically controlled for to reduce 
the probability that epistatic interactions accounted for the observed GxE findings.  
Finally, multiple ischmia/hypoxia regulated genes were found to interact with fetal 
growth compromise to predict AD/HD. This evidence suggests that fetal growth 
compromise moderates ischemia/hypoxia regulated genes in angiogenic and neurotrophic 
pathways to predict AD/HD.  
 If replicated, future research should examine the underpinnings of the observed 
GxE findings. For example, studies may examine the role of epigenetic mechanisms 
underlying the observed SNP x birth weight centile range interactions predicting AD/HD. 
Twin studies may investigate the differences in DNA methylation of angiogenic and 
neurotropic pathway genes in monozygotic twins who are discordant for AD/HD.  Such 
studies would follow up on previous MZ discordant twin studies in AD/HD (Hultman et 
al., 2007; Lehn et al., 2007; Pearsall-Jones et al., 2008; Sharp et al., 2003) to examine 
epigenetic mechanisms linking fetal growth compromise to AD/HD.  
 Fetal growth compromise, angiogenic genes, and neurotrophic genes are 
associated with a wide range of psychiatric disorders. Given that the gene and 
environmental risk factors in this study are not specific to AD/HD, findings may 
generalize to other neurodevelopmental disorders. For example, identifying how the 
observed GxE interactions relate to neuroanatomical or neurofunctional outcomes may 
help to elucidate neurodevelopmental pathways to neurodevelopmental disorders, more 
generally. Furthermore, multiple genes are regulated by ischmia/hypoxia and a more 
comprehensive analysis may identify other candidate genes or pathways that interact with 
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fetal growth compromise to predict AD/HD.  For example, Oades (2011) demonstrated 
that prenatal risk factors were associated with alterations in kynurenine and cytokine 
metabolism in youth with AD/HD. An expanded analysis of this study also suggests that 
fetal growth compromise moderates associations between kynurenine variants and 
AD/HD symptom severity (Smith et al., In preparation). It is also important to identify 
the true environmental pathogen(s) that moderates the relationship between angiogenic 
and neurotrophic variants and AD/HD. Animal studies may help to disentangle the 
effects of prenatal and postnatal environmental factors on neurodevelopment and AD/HD 
symptomatology. In addition, human studies may look to further refine the measurement 
of prenatal ischemia/hypoxia by taking direct measurements during fetal development or 
by taking a latent variable approach using pregnancy, delivery and birth outcome 
indicators.   
Conclusion 
The current study examined the role of fetal growth compromise in moderating 
relationships between SNPs within angiogenic, neurotrophic, and dopamine genes and 
AD/HD symptom severity. In an extension of previous research, this study suggests that: 
1) angiogenic genes play a role in the etiology of AD/HD; and 2) fetal growth 
compromise moderates associations between SNPs within angiogenic and neurotrophic 
genes and AD/HD symptom severity. This suggests that angiogenic and neurotrophic 
factor response to a restricted nutrient supply in utero modifies vulnerability for AD/HD. 
This study also suggests that the DOHaD hypothesis (Gluckman & Hanson, 2004) is a 
useful framework to conceptualize how a restricted nutrient supply in utero confers risk 
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for AD/HD. If replicated, these findings may help to guide the search for epigenetic 
mechanisms which modify vulnerability for AD/HD and can be targeted by interventions.  
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APPENDIX A:  
 
TABLES AND FIGURES 
 
Table 1  
 
Sample Size by Site 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. NCGAP = 
North Carolina Genetics of ADHD Project. UNCG = University of North Carolina at 
Greensboro. IMAGE = International Multisite ADHD Genetics Project  
 
Site n % of total sample 
NCGAP Subtotal 107 26.9 
     Duke   65 16.3 
     UNCG   42 10.6 
   
IMAGE Subtotal 291 73.1 
     Ireland   84 21.1 
     Netherlands-Amsterdam 101 25.4 
     Netherlands-Nijmegen   73 18.3 
     United Kingdom   33   8.3 
   
Total Sample 398 100 
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Table 2  
Sample Characteristics  
 NCGAP IMAGE Total 
 M SD M SD M SD 
Age  8.59 2.54 11.50 2.80 10.72 3.02 
       
 Percentage N Percentage N Percentage N 
Male 30.84 74 87.62 255 82.66 329 
Female 69.16 33 12.37 36 17.34 38 
       
Proband 67.29 72 98.97 288 360 90.45 
Sibling 32.71 35 1.03 3 38 9.55 
Note. NCGAP = North Carolina Genetics of ADHD Project. IMAGE = International 
Multisite ADHD Genetics Project  
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Table 3 
AD/HD Clinical Characteristics 
 IMAGE NCGAP Total 
 M SD M SD M SD 
CPRS ADHD Total 78.68 8.49 74.61 14.11 77.59 10.45 
CPRS DSM-IV IA  72.44 8.47 70.75 13.60 71.98 10.12 
CPRS DSM-IV HI 80.80 9.08 73.08 14.69 78.73 11.38 
CTRS ADHD Total 69.98 11.75 62.86 11.66 66.75 11.91 
CTRS DSM-IV IA 64.84 10.09 63.10 12.14 64.42 10.62 
CTRS DSM-IV HI 68.08 13.29 59.76 12.79 66.09 13.63 
IA Symptoms 8.11 1.15 7.54 1.70 7.97 1.32 
HI Symptoms 8.03 1.29 5.80 2.85 7.49 2.03 
Note. CPRS = Conners Parent Rating Scale. CTRS = Conners Teacher Rating Scale. IA = 
Inattention. HI = Hyperactive-Impulsive. CTRS data on 286 IMAGE and 90 NCGAP 
youth.  
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Table 4 
AD/HD and Comorbidity 
 IMAGE NCGAP Total 
 % N % N % N 
AD/HD Subtype       
     Combined Type 94.50 275 48.60 52 82.16 327 
     Predominantly IA Type 3.09 9 30.84 33 10.55 42 
     Predominantly HI Type 1.72 5 6.54 7 3.02 12 
     Unaffected .69 2 14.02 15 4.27 17 
Oppositional Defiant 
Disorder 
68.17 197 34.91 37 59.24 234 
Conduct Disorder 28.03 81 4.72 5 21.77 86 
Mood Disorder 22.84 66 4.72 5 17.97 71 
Bipolar Disorder 1.04 3 0  0 .76 3 
Anxiety Disorder 51.56 149 13.21 14 41.27 163 
Obsessive-Compulsive 
Disorder 
6.23 18 .09 1 4.8 19 
Tic Disorder 3.80 11 5.66 6 4.30 17 
Substance Abuse Disorder 1.38 4 0 0 1.01 4 
Note. Comorbidity N=395. IA = Inattentive; HI = Hyperactive-Impulsive. 
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Table 5 
Pregnancy, Birth and Delivery Characteristics 
 IMAGE NCGAP Total Differences Between 
Studies 
 % N % N % N χ
2 
p-
value 
% 
Missing 
Maternal Smoking  22.3 65 7.8 8 18.6 73 10.49 <.01 1.3 
Paternal Smoking 38.8 100 22.2 22 34.2 122 8.70 <.01 10.3 
Maternal Alcohol 
Use 
25.5 73 2.0 2 19.4 75 26.19 <.01 3.0 
Anemia 6.9 20 8.7 6 7.2 26 .28 .60 9.5 
High Blood Pressure 7.9 23 11.2 10 8.7 33 .95 .33 4.5 
Kidney Disorder 0 0 1.1 1 .3 1 3.32 .07 4.8 
Toxemia 1.4 4 7.9 7 2.9 11 10.21 <.01 4.5 
Rh Incompatibility 0 0 9.0 8 2.1 8 26.72 <.01 4.5 
Cesarean  Section 4.1 12 30.3 27 10.3 39 50.85 <.01 4.5 
Premature Labor .3 1 14 12 3.4 13 36.93 <.01 5.3 
Delivery Induced 9.3 27 32.6 29 14.7 56 29.46 <.01 4.5 
Forceps 2.4 7 11.5 10 4.5 17 12.88 <.01 5.0 
Breech Delivery .7 2 2.3 2 1.1 4 1.63 .20 4.8 
Trouble Breathing 6.9 20 10.1 9 7.6 29 1.02 .31 4.5 
Needed Oxygen 4.1 12 10.5 9 5.6 21 5.08 .02 5.3 
Cyanotic 4.5 13 8.0 7 5.3 20 1.64 .20 4.8 
Jaundiced 3.8 11 25.8 23 8.9 34 40.72 <.01 4.5 
Infection 0 0 5.6 5 1.3 5 16.57 <.01 4.5 
Seizures 0 0 0 0 0 0 - - 4.5 
Given Medication 0 0 8.0 7 1.8 7 23.58 <.01 4.8 
Hospital for > 6 days 0 0 5.7 5 1.3 5 16.76 <.01 4.8 
Note. NCGAP = North Carolina Genetics of ADHD Project. IMAGE = International 
Multisite ADHD Genetics Project.  
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Table 6 
 
Correlations Between Selected Demographic, ADHD, and Perinatal Variables 
 
 
Age 
CPRS 
ADHD 
Total  
Birth 
Weight 
Centile 
Range 
Birth 
Weight 
(g) 
Gestational 
Age 
Maternal 
Smoking 
Paternal 
Smoking 
Maternal 
Alcohol 
Use 
Age r 1 .21
*
 -.14
*
 -.08 .08 -.04 -.05 -.03 
N 398 398 398 398 398 398 365 398 
CPRS ADHD Total  r .21
*
 1 .02 .04 .10 -.09 -.19
*
 -.04 
N 398 398 398 398 398 398 365 398 
Birth Weight Centile 
Range 
r -.14
*
 .02 1 .76
*
 -.09 -.04 -.00 -.05 
N 398 398 398 398 398 398 365 398 
Birth Weight (g) r -.08 .04 .76
*
 1 .50
*
 -.10 -.05 -.06 
N 398 398 398 398 398 398 365 398 
Gestational Age r .08  .10 -.09 .50
*
 1 -.10 -.07 -.05 
N 398 398 398 398 398 398 365 398 
Maternal Smoking r -.04 -.09 -.04 -.10 -.10 1 .72
*
 .11 
N 398 398 398 398 398 398 365 398 
Paternal Smoking r -.05 -.19
*
 -.00 -.05 -.07 .72
*
 1 .06 
N 365 365 365 365 365 365 365 365 
Maternal Alcohol Use r -.03 -.04 -.05 -.06 -.05 .11 .06 1 
N 398 398 398 398 398 398 365 398 
Note. CPRS = Conners’ Parent Rating Scale. Maternal smoking, paternal smoking and maternal alcohol use are binary 
variables for where 1 = any reported use during the pregnancy and 0 = no reported use during the pregnancy. * = correlation is 
significant at the 0.01 level (2-tailed). 
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Table 7  
Main Effects of SNPs and Interactions between SNPs and Birth Weight Centile Range Predicting the Transformed CPRS 
ADHD Total Score 
      p-values (no covariate model) p-values (covariate model) 
System Gene NCBI36 SNP 
Allele 
(Freq) 
# of 
Youth 
SNP Main Effect 
Interacti
on 
SNP Main 
Effect 
Interaction 
Neurotrophic NTRK2 86522947 rs11141486 G (0.31) 397 0.697 0.084 0.862 0.012 
Angiogenic NRP2 206285589 rs17682318 C (0.28) 392 0.904 0.018 1.000 0.016 
Angiogenic NRP1 33634008 rs2065364 T (0.28) 396 0.691 0.043 0.487 0.018 
Angiogenic NRP2 206272281 rs10932118 T (0.45) 397 0.441 0.013 0.442 0.022 
Neurotrophic NTRK3 86265616 rs8031510 C (0.22) 384 0.992 0.074 0.838 0.035 
Angiogenic VEGFR1 27835419 rs9513089 A (0.36) 396 0.270 0.023 0.150 0.037 
Angiogenic NRP2 206279650 rs12611613 G (0.39) 398 0.882 0.018 0.958 0.038 
Angiogenic NRP1 33524702 rs734187 A (0.22) 396 0.875 0.006 0.599 0.045 
Dopaminergic DRD3 115345577 rs963468 A (0.42) 398 0.905 0.014 0.937 0.056 
Angiogenic NRP1 33585470 rs10827221 C (0.32) 398 0.830 0.063 0.947 0.065 
Dopaminergic DRD3 115340891 rs2134655 T (0.26) 398 0.885 0.142 0.551 0.078 
Dopaminergic DAT1 1481135 rs10053602 C (0.23) 397 0.437 0.055 0.581 0.085 
Neurotrophic BDNF 27671460 rs7127507 C (0.31) 396 0.018 0.384 0.025 0.088 
Neurotrophic BDNF 27636492 rs6265 T (0.20) 398 0.070 0.324 0.033 0.090 
Angiogenic VEGFR1 27904847 rs3794405 C (0.24) 397 0.812 0.096 0.471 0.100 
Dopaminergic DRD2 112834984 rs7131056 A (0.48) 396 0.273 0.284 0.156 0.104 
Neurotrophic NTRK3 86391497 rs1948066 T (0.33) 397 0.149 0.089 0.091 0.109 
Dopaminergic DAT1 1485202 rs456774 C (0.22) 393 0.059 0.124 0.047 0.127 
Neurotrophic NGFB 115655119 rs556723 T (0.3) 398 0.320 0.105 0.263 0.132 
Angiogenic NRP1 33587815 rs3780867 A (0.50) 398 0.812 0.171 0.796 0.143 
Neurotrophic BDNF 27656701 rs7103411 C (0.21) 397 0.125 0.324 0.067 0.147 
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      p-values (no covariate model) p-values (covariate model) 
System Gene NCBI36 SNP 
Allele 
(Freq) 
# of 
Youth 
SNP Main 
Effect 
Interaction 
SNP Main 
Effect 
Interaction 
Angiogenic NRP1 33613812 rs7079372 T (0.20) 398 0.980 0.068 0.947 0.150 
Neurotrophic NTRK3 86364875 rs999905 C (0.34) 398 0.030 0.146 0.036 0.159 
Angiogenic NRP1 33593263 rs2073320 A (0.38) 397 0.538 0.192 0.510 0.161 
Angiogenic NRP2 206344344 rs849511 G (0.50) 395 0.952 0.289 0.936 0.186 
Dopaminergic DRD2 112823183 rs4245146 T (0.45) 398 0.087 0.366 0.802 0.188 
Angiogenic NRP2 206301921 rs13018627 G (0.45) 384 0.701 0.484 0.779 0.234 
Neurotrophic NTRK2 86661581 rs452723 T (0.41) 387 0.202 0.321 0.723 0.237 
Angiogenic HIF1AN 102285826 rs2295778 G (0.27) 383 0.049 0.342 0.182 0.250 
Angiogenic NRP2 206370927 rs11678877 G (0.48) 396 0.666 0.464 0.742 0.260 
Neurotrophic NTRK2 86673280 rs1952348 A (0.44) 395 0.360 0.265 0.148 0.279 
Neurotrophic NTRK3 86336921 rs4887346 C (0.44) 396 0.381 0.280 0.447 0.281 
Neurotrophic NTRK3 86289432 rs1369426 A (0.49) 398 0.351 0.353 0.167 0.284 
Angiogenic VEGFR1 27839060 rs7995976 A (0.24) 398 0.986 0.401 0.556 0.286 
Angiogenic NRP1 33608278 rs2776925 G (0.36) 398 0.712 0.467 0.806 0.298 
Angiogenic VEGFA 43855555 rs3025010 C (0.32) 398 0.676 0.639 0.580 0.299 
Neurotrophic NTRK3 86459135 rs4887362 C (0.3) 386 0.410 0.288 0.814 0.319 
Neurotrophic NTRK2 86500477 rs10868456 A (0.37) 390 0.115 0.607 0.172 0.359 
Neurotrophic NTRK3 86518284 rs7179806 C (0.28) 394 0.862 0.316 0.865 0.372 
Neurotrophic NTRK3 86262610 rs1347424 T (0.34) 398 0.052 0.566 0.059 0.398 
Neurotrophic NTRK3 86303546 rs8038245 G (0.46) 396 0.237 0.338 0.171 0.417 
Dopaminergic COMT 18326686 rs4646316 T (0.26) 392 0.751 0.762 0.619 0.420 
Angiogenic NRP1 33618294 rs4934858 C (0.36) 398 0.496 0.433 0.738 0.421 
Neurotrophic NTRK3 86519246 rs13329385 C (0.23) 397 0.495 0.629 0.655 0.436 
Angiogenic VEGFR1 27867458 rs2104330 C (0.47) 395 0.084 0.909 0.019 0.443 
Neurotrophic NTRK3 86538332 rs4887381 T (0.22) 386 0.328 0.147 0.511 0.447 
Neurotrophic BDNF 27656893 rs7103873 C (0.48) 398 0.234 0.749 0.459 0.453 
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      p-values (no covariate model) p-values (covariate model) 
System Gene NCBI36 SNP 
Allele 
(Freq) 
# of 
Youth 
SNP Main 
Effect 
Interaction 
SNP Main 
Effect 
Interaction 
Neurotrophic NTRK3 86294898 rs7178071 G (0.21) 385 0.400 0.703 0.488 0.476 
Neurotrophic NTRK2 86588285 rs10119168 A (0.46) 386 0.119 0.062 0.166 0.496 
Angiogenic NRP1 33638553 rs12358711 A (0.44) 392 0.353 0.408 0.069 0.505 
Dopaminergic DRD2 112786283 rs6279 G (0.3) 396 0.830 0.659 0.622 0.510 
Neurotrophic NTRK3 86403845 rs3825885 C (0.32) 396 0.015 0.379 0.010 0.525 
Neurotrophic NTRK3 86266972 rs1007533 C (0.43) 386 0.424 0.594 0.320 0.571 
Angiogenic VEGFR1 27871621 rs9319428 A (0.31) 374 0.876 0.545 0.767 0.578 
Angiogenic NRP2 206263877 rs10194604 G (0.45) 386 0.954 0.490 0.988 0.579 
Neurotrophic NTRK3 86520227 rs4887376 G (0.47) 391 0.544 0.572 0.467 0.584 
Neurotrophic NTRK3 86390889 rs3784432 T (0.34) 385 0.207 0.080 0.244 0.593 
Neurotrophic NTRK2 86485592 rs7860382 C (0.36) 396 0.191 0.378 0.489 0.597 
Angiogenic HIF1AN 102303597 rs11292 G (0.21) 398 0.721 0.686 0.521 0.608 
Dopaminergic DAT1 1489408 rs420422 C (0.45) 386 0.172 0.537 0.187 0.627 
Neurotrophic NTRK2 86651130 rs7033669 T (0.26) 394 0.183 0.433 0.389 0.635 
Neurotrophic NTRK2 86597888 rs10514832 A (0.26) 398 0.832 0.262 0.300 0.639 
Neurotrophic NTRK2 86677554 rs10780796 T (0.40) 397 0.058 0.293 0.044 0.643 
Angiogenic VEGFR1 27905143 rs9513113 T (0.38) 397 0.504 0.930 0.705 0.646 
Dopaminergic DRD2 112810524 rs12364051 A (0.43) 393 0.428 0.603 0.525 0.652 
Angiogenic NRP1 33515288 rs2228638 T (0.11) 398 0.868 0.744 0.813 0.667 
Neurotrophic NTRK3 86241794 rs1435402 C (0.37) 396 0.356 0.567 0.241 0.704 
Angiogenic NRP1 33645638 rs2768420 G (0.3) 396 0.696 0.754 0.611 0.708 
Neurotrophic NTRK2 86670391 rs4878017 A (0.37) 397 0.092 0.764 0.208 0.718 
Angiogenic VEGFR2 55675376 rs6832059 C (0.49) 394 0.450 0.959 0.348 0.721 
Neurotrophic NTRK2 86542525 rs962658 C (0.43) 398 0.935 0.944 0.982 0.723 
Angiogenic VEGFR2 55646483 rs2067951 C (0.49) 398 0.026 0.583 0.077 0.750 
Neurotrophic NTRK2 86482260 rs10512176 C (0.29) 397 0.190 0.806 0.342 0.750 
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      p-values (no covariate model) p-values (covariate model) 
System Gene NCBI36 SNP 
Allele 
(Freq) 
# of 
Youth 
SNP Main 
Effect 
Interaction 
SNP Main 
Effect 
Interaction 
Angiogenic NRP1 33607139 rs10827228 T (0.48) 397 0.966 0.580 0.996 0.759 
Neurotrophic NTRK3 86447926 rs16941255 G (0.53) 391 0.146 0.445 0.105 0.762 
Angiogenic NRP1 33602908 rs9299707 T (0.24) 397 0.960 0.855 0.827 0.765 
Angiogenic VEGFR2 55681048 rs4317261 T (0.31) 398 0.207 0.552 0.103 0.765 
Angiogenic VEGFR1 27894418 rs9319434 T (0.27) 385 0.928 0.688 0.993 0.775 
Neurotrophic NTRK2 86649401 rs7048294 C (0.27) 397 0.340 0.483 0.640 0.789 
Neurotrophic NTRK2 86547033 rs10746782 A (0.35) 398 0.848 0.512 0.750 0.794 
Neurotrophic NTRK2 86604868 rs994029 C (0.40) 398 0.048 0.590 0.099 0.810 
Neurotrophic NTRK3 86530483 rs1346164 C (0.32) 384 0.481 0.958 0.907 0.813 
Dopaminergic DRD3 115373505 rs6280 C (0.31) 398 0.010 0.927 0.065 0.829 
Neurotrophic NTRK3 86595863 rs4887400 C (0.35) 398 0.197 0.387 0.084 0.830 
Neurotrophic NTRK2 86497392 rs7858590 T (0.40) 388 0.544 0.673 0.774 0.869 
Angiogenic HIF1A 61276301 rs2301113 C (0.21) 385 0.998 0.937 0.731 0.870 
Angiogenic VEGFR1 27781061 rs7993418 G (0.20) 397 0.746 0.489 0.843 0.885 
Angiogenic NRP1 33550669 rs4934838 A (0.25) 397 0.985 0.724 0.910 0.887 
Angiogenic VEGFR1 27918256 rs7330109 T (0.31) 398 0.365 0.614 0.461 0.890 
CD1 CD1B 155116945 rs716221 T (0.21) 397 0.599 0.891 0.718 0.903 
Dopaminergic COMT 18324789 rs4633 C (0.49) 398 0.315 0.847 0.506 0.904 
Angiogenic VEGFR2 55660296 rs10016788 G (0.45) 393 0.033 0.895 0.023 0.940 
CD1 CD1B 155108702 rs10797007 G (0.33) 395 0.636 0.969 0.672 0.947 
Angiogenic NRP1 33565842 rs927099 T (0.48) 396 0.341 0.758 0.256 0.974 
Neurotrophic NTRK3 86470167 rs1426300 C (0.52) 388 0.286 0.961 0.134 0.974 
Angiogenic VEGFR1 27956068 rs12858139 A (0.45) 396 0.627 0.758 0.384 0.979 
Angiogenic NRP1 33583935 rs1319013 T (0.46) 396 0.855 0.608 0.377 0.983 
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Table 8 
Mean CPRS AD/HD Total Score by Minor Allele Genotype for Nominally Significant 
Main Effect SNPs 
Gene SNP Minor Allele 0 1 2 
BDNF rs6265 T 
78.18 (10.21) 77.11 (10.33) 70.69 (13.94) 
n = 255 n = 130 n = 13 
BDNF rs7127507 C 
76.27 (11.14) 78.20 (9.83) 81.03 (8.53) 
n = 189 n = 169 n = 38 
COMT rs9332377 T 
77.90 (10.37) 76.49 (9.65) 84.50 (0.71) 
n = 286 n = 93 N = 2 
DAT1 rs456774 C 
76.94 (10.88) 78.85 (9.27) 80.96 (7.95) 
n = 245 n = 125 n = 23 
DRD2 rs4350392 A 
77.01 (10.96) 78.80 (8.62) 84.14 (6.47) 
n = 297 n = 93 n = 7 
DRD3 rs324035 A 
77.73 (10.18) 76.79 (11.13) 84.43 (2.88) 
n = 267 n = 123 n = 7 
NRP1 rs2474712 C 
78.20 (10.09) 77.16 (10.41) 69.93 (13.73) 
n = 255 n = 127 n = 15 
NRP1 rs2776930 C 
77.49 (10.77) 77.49 (9.42) 86.00 (4.58) 
n = 304 n = 88 n = 3 
NTRK2 rs10780796 T 
75.99 (11.25) 78.62 (10.11) 78.40 (8.73) 
n = 142 n = 195 n = 60 
NTRK3 rs999905 C 
78.67 (10.03) 77.51 (10.20) 73.98 (11.99) 
n = 182 n = 165 n = 51 
NTRK3 rs3825885 C 
77.59 (10.82) 78.84 (8.91) 72.91 (13.20) 
n = 184 n = 169 n = 43 
NTRK3 rs7176444 G 
77.71 (10.66) 77.68 (8.11) 88.50 (2.12) 
n = 329 n = 57 n = 2 
NTRK3 rs8037291 G 
77.51 (10.00) 79.93 (9.66) 74.00 (8.80) 
n = 268 n = 104 n = 9 
VEGFR1 rs2104330 C 
79.05 (8.88) 76.48 (10.95) 79.21 (8.45) 
n = 104 n = 210 n = 81 
VEGFR2 rs10016788 G 
79.42 (8.80) 76.07 (11.79) 78.65 (8.58) 
n = 104 n = 196 n = 78 
Note. Standard Deviation in ().
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Table 9 
Main Effect of SNPs with MAF between .10 and .20 and Interaction between SNPs and Birth Weight Centile Range Predicting 
the Transformed CPRS ADHD Total Score 
      p - value FDR q -value 
System Gene NCBI36 SNP 
Allele 
(Freq) 
# of 
Youth 
SNP Main 
Effect Interaction 
SNP Main 
Effect Interaction 
Angiogenic HIF1A 61283601 rs2057482 T (0.13) 390 0.2105 <0.0001 0.6589 <0.0001 
Angiogenic HIF1A 61236316 rs2301106 C (0.11) 398 0.2645 <0.0001 0.7053 <0.0001 
Neurotrophic NTRK3 86558642 rs7176444 G (0.08) 388 0.0434 <0.0001 0.4803 <0.0001 
Angiogenic NRP1 33589567 rs11598845 C (0.14) 390 0.2519 <0.0001 0.7113 <0.0001 
CD1 CD1B 155113379 rs962879 C (0.12) 398 0.8905 <0.0001 1.0018 0.0001 
Neurotrophic NTRK3 86308935 rs8037291 G (0.16) 381 0.0190 0.0003 0.4558 0.0071 
Neurotrophic NTRK3 86426100 rs17755717 A (0.2) 378 0.4665 0.0030 0.9077 0.0616 
Neurotrophic NTRK3 86355556 rs1017757 G (0.13) 391 0.0977 0.0064 0.5864 0.1148 
Angiogenic NRP1 33627887 rs2776930 C (0.12) 395 <0.0001 0.0151 0.0002 0.2176 
Angiogenic NRP1 33636052 rs4934901 T (0.17) 396 0.6243 0.0157 0.9268 0.2059 
Angiogenic NRP1 33645682 rs2804493 A (0.14) 396 0.2964 0.0298 0.7358 0.2862 
Neurotrophic NTRK3 86465797 rs2114251 A (0.17) 385 0.3781 0.0463 0.8249 0.3332 
Angiogenic NRP2 206266851 rs13419677 C (0.16) 396 0.0719 0.0679 0.5179 0.4254 
Dopaminergic DRD3 115351544 rs324035 A (0.17) 397 0.0010 0.0685 0.0487 0.4110 
Angiogenic VEGFR1 27937214 rs622227 C (0.14) 398 0.6350 0.0986 0.9331 0.4895 
Angiogenic NRP1 33588382 rs10490938 T (0.18) 398 0.1953 0.1007 0.6393 0.4679 
Dopaminergic DRD2 112787300 rs1124491 A (0.16) 395 0.8959 0.1360 1.0001 0.5441 
Angiogenic NRP1 33566833 rs12765284 A (0.11) 394 0.5927 0.1492 0.9378 0.5509 
Neurotrophic NTRK3 86254661 rs6496455 A (0.16) 382 0.7647 0.1699 0.9921 0.5691 
Angiogenic NRP1 33587471 rs3780869 T (0.16) 398 0.7930 0.1715 0.9929 0.5614 
Angiogenic VEGFR1 27866510 rs17537653 A (0.13) 378 0.9525 0.2181 0.9940 0.6683 
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      p - value FDR q -value 
System Gene NCBI36 SNP 
Allele 
(Freq) 
# of 
Youth SNP Main Effect 
Interacti
on SNP Main Effect 
Interactio
n 
Dopaminergic DRD2 112840927 rs4350392 A (0.13) 397 0.0186 0.2281 0.5370 0.6844 
Angiogenic NRP1 33511136 rs2506145 C (0.12) 398 0.1941 0.2350 0.6499 0.6767 
Neurotrophic NTRK3 86265806 rs1836592 A (0.21) 392 0.2878 0.2857 0.7270 0.7217 
Angiogenic NRP1 33597285 rs10827224 C (0.16) 398 0.6040 0.2977 0.9352 0.7267 
Angiogenic VEGFA 43859053 rs3025033 G (0.14) 398 0.1070 0.3961 0.5315 0.8776 
Angiogenic NRP1 33569034 rs2269091 T (0.19) 393 0.1675 0.4304 0.6346 0.8853 
Angiogenic NRP1 33508175 rs2506143 G (0.14) 394 0.3567 0.4710 0.8026 0.9044 
Neurotrophic NTRK3 86358314 rs1350799 C (0.12) 390 0.2345 0.5061 0.7185 0.9225 
Angiogenic NRP1 33639848 rs2776934 G (0.16) 388 0.7144 0.5084 0.9891 0.9152 
Angiogenic NRP1 33603899 rs2243668 A (0.12) 397 0.8573 0.5993 0.9876 0.9696 
Angiogenic NRP1 33560360 rs11009311 A (0.17) 395 0.9109 0.6025 0.9937 0.9641 
Angiogenic NRP1 33652767 rs10827234 C (0.16) 396 0.9492 0.6212 0.9977 0.9722 
Angiogenic VEGFR2 55672161 rs6554217 T (0.18) 385 0.5472 0.6527 0.9271 0.9493 
Neurotrophic NTRK2 86664490 rs1576161 T (0.17) 398 0.2458 0.6711 0.7079 0.9568 
Angiogenic NRP2 206278364 rs10432438 T (0.17) 391 0.1013 0.7697 0.5609 0.9809 
Angiogenic NRP1 33506572 rs1044268 T (0.12) 398 0.4080 0.7823 0.8514 0.9795 
Neurotrophic NTRK3 86454485 rs3784415 C (0.12) 392 0.1487 0.7850 0.6691 0.9745 
Angiogenic NRP1 33574886 rs10490939 A (0.15) 397 0.2686 0.8120 0.7034 0.9744 
Angiogenic VEGFR1 27807835 rs7982251 C (0.14) 395 0.5508 0.8187 0.9223 0.9664 
Angiogenic HIF1A 61259284 rs4899056 T (0.12) 381 0.6531 0.8247 0.9405 0.9656 
Dopaminergic DRD2 112792088 rs2440390 T (0.14) 395 0.8285 0.8370 0.9779 0.9565 
Angiogenic NRP1 33551053 rs2273466 C (0.18) 398 0.2966 0.8890 0.7238 0.9772 
Dopaminergic COMT 18330246 rs9332377 T (0.13) 381 <0.0001 0.9364 <0.0001 0.9988 
CD1 CD1B 155107015 rs10908647 G (0.11) 396 0.2823 0.9468 0.7258 0.9952 
Dopaminergic DRD2 112811975 rs4436578 C (0.11) 394 0.1515 0.9550 0.6415 0.9893 
Angiogenic NRP1 33537715 rs2474712 C (0.2) 397 0.0224 0.9713 0.4040 0.9990 
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Table 10  
Location and Function of SNPs Involved in Significant GxE Interactions 
System 
Chromosome 
Location Gene SNP 
Location in 
Gene Function 
Angiogenic 14q21-24 HIF1A rs2057482 3’ UTR Transcriptional regulation 
Angiogenic 14q21-24 HIF1A rs2301106 Intron Transcriptional regulation 
Neurotrophic 15q25 NTRK3 rs7176444 Intron Transcriptional regulation 
Angiogenic 10p12 NRP1 rs11598845 Intron No none function 
CD1 1q21-q22 CD1B rs962879 Intron Transcriptional regulation 
Neurotrophic 15q25 NTRK3 rs8037291 Intron No none function 
Note. SNP function reported from F-SNP (http://compbio.cs.queensu.ca/F-SNP/; Lee & 
Shatkay, 2008). 
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Figure 1. Model of the complex interplay between genetic and environmental factors underlying the association between 
AD/HD and low birth weight. Intergen. = Intergenerational; Environ. = Environment; LBW =  Low Birth Weight; ND = 
Neurodevelopmental. 
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Figure 2. Nominally significant SNP within angiogenic genes by birth weight centile 
range interactions predicting ADHD symptom severity.  p -value for each interaction < 
.05 after controlling for age, sex, research site and main effects of SNP and birth weight 
centile range.  
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Figure 2 (Continued). Nominally significant SNP within angiogenic genes by birth weight 
centile range interactions predicting ADHD symptom severity.  p -value for each 
interaction < .05 after controlling for age, sex, research site and main effects of SNP and 
birth weight centile range.
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Figure 2 (Continued). Nominally significant SNP within angiogenic genes by birth weight 
centile range interactions predicting ADHD symptom severity.  p -value for each 
interaction < .05 after controlling for age, sex, research site and main effects of SNP and 
birth weight centile range.
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Figure 3. Nominally significant SNP within neurotrophic genes by birth weight centile 
range interactions predicting ADHD symptom severity. p-value for each interaction < .05 
after controlling for age, sex, research site and main effects of SNP and birth weight 
centile range.  
 
 
 
 
          
74
76
78
80
82
84
10th-16th percentile 84th-90th percentile
C
P
R
S
 A
D
H
D
 T
o
ta
l 
T
-S
co
re
 
Birth Weight Centile Range 
NTRK3 - rs8031510 - C  
74
76
78
80
82
84
10th-16th percentile 84th-90th percentile
C
P
R
S
 A
D
H
D
 T
o
ta
l 
T
-S
co
re
 
Birth Weight Centile Range 
NTRK2 - rs11141486 - G 
0 1 2
 Minor Allele Genotype 
 
120 
 
Figure 4. SNP minor allele genotype by birth weight centile range interaction predicting 
ADHD symptom severity. FDR adjusted p-value for each interaction < .05 after 
controlling for research site, age, and sex, and main effects of SNPs and birth weight 
centile range.  
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Figure 4 (Continued). SNP minor allele genotype by birth weight centile range 
interaction predicting ADHD symptom severity. FDR adjusted p-value for each 
interaction < .05 after controlling for research site, age, and sex, and main effects of 
SNPs and birth weight centile range.  
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Figure 4 (Continued). SNP minor allele genotype by birth weight centile range 
interaction predicting ADHD symptom severity. FDR adjusted p-value for each 
interaction < .05 after controlling for research site, age, and sex, and main effects of 
SNPs and birth weight centile range.  
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Figure 5. Proposed model of epigenetic processes mediating the relationship between 
gene-environment interaction and AD/HD. 
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APPENDIX B:  
 
MEASURES 
 
 
DEVELOPMENTAL HISTORY 
 
I. PREGNANCY AND DELIVERY    Child's Name:____________ 
Length of pregnancy (e.g., full term or 40 weeks, 32 weeks, etc.)   ______ 
Length of delivery (number of hours from initial labor pains to birth)  ______ 
Mother's age when child was born       ______ 
Was the pregnancy with this child under a doctor's care?    ______ 
Was the pregnancy a multiple birth (twins, triplets, etc)?    ______ 
Did any of the following conditions occur during pregnancy/delivery? 
 NO YES 
Anemia   
High blood pressure   
Swollen ankles   
Kidney disease   
Bleeding   
Excessive weight gain (more than 30 pounds)   
Toxemia/Preeclampsia   
Rh factor incompatibility   
Frequent nausea or vomiting   
Measles   
German Measles   
Flu   
Strep throat   
Other illness or injury   
Took prescription medication 
If YES, name of medication: 
  
Took illegal drugs   
Used alcoholic beverages 
If YES, approximate number of drinks per week: 
  
Smoked cigarettes 
If YES, approximate number of cigarettes per day: 
  
Was given medication to ease labor pains:   
Threatened miscarriage   
Premature labor   
Delivery was induced   
Had a breech delivery   
Had a Cesarean section delivery   
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Severe emotional problems   
Emotional distress   
Other problems….Please describe:   
 
Did any of the following affect your child during delivery or within the first few days 
after birth? 
 NO YES 
Injured during delivery   
Cardiopulmonary distress during deliver   
Delivered with cord around neck   
Had trouble breathing following delivery   
Needed oxygen   
Was cyanotic, turned blue   
Was jaundiced, turned yellow   
Had an infection   
Had seizures   
Was given medications   
Born with congenital defect   
Was in hospital more than seven days   
 
